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ABSTRACT 
 
Beta amyloid (Aβ) plays a central role in the pathogenesis of Alzheimer’s disease 
(AD).  It is produced by the sequential cleavage of amyloid precursor protein (APP) by 
β- and γ-secretases.  This amyloidogenic pathway produces peptides 38-42 amino 
acids in length, based on the sites cleaved by γ-secretase. Aβ1-42 is the predominant 
peptide species found in neuritic plaques. Its accumulation and impaired clearance are 
associated with disease progression. An alternative pathway has been proposed 
wherein short, N-terminal Aβ fragments are produced. The N-terminal fragments are 
hydrophilic, making them soluble and less likely to aggregate into plaques.  Aβ1-15 is the 
N-terminal Aβ fragment of focus in this study.  It is produced by the sequential cleavage 
of APP by β- and α-secretases followed by a carboxypeptidase. Aβ1-15 is also 
upregulated in AD patients suggesting a possible compensatory switch between 
pathways to suppress Aβ1-42 production. We have recently shown that Aβ1-15 can 
enhance long-term potentiation (LTP) in wild-type hippocampal synapses at very low 
(fΜ) concentrations. Aβ1-15 was also shown to reverse the LTP block incurred by Aβ1-42, 
as well as rescue LTP deficits in APPswe mice. This fragment has a potent and 
effective signaling activity via nicotinic acetylcholine receptors (nAChRs). Taken 
together, these data support a neuromodulatory function and a possible neuroprotective 
action for Aβ1-15.  This study focuses on the effects of Aβ1-15 on Aβ1-42 toxicity in various 
neuronal models, including in vitro NG108-15 hybrid neuroblastoma cells, ex vivo 
hippocampal neuron cultures and in vivo wild-type and AD model-APP mice.   
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We explored Aβ1-15 neuroprotection against Aβ-mediated neurodegeneration in 
vitro by incubating our differentiated neuroblastoma cell line with different treatment 
combinations and across different time points in order to examine both the potency of 
Aβ1-15 as well as the different ways by which Aβ1-15 might be affecting Aβ1-42 toxicity.  
Specifically, we explored the possibilities of Aβ1-15 priming by pretreating cells with Aβ1-
15 before the addition of the toxic Aβ1-42, competition of the two fragments by 
combination treatment, or rescue experiments by adding Aβ1-15 after addition of Aβ1-42 to 
determine whether Aβ1-15 can reverse or halt toxicity caused by Aβ1-42. Cellular toxicity 
was assessed as oxidative stress (production of reactive oxygen species, ROS) and 
apoptotic cell death.  Next, we investigated the neuroprotective effects of Aβ1-15 ex-vivo 
by establishing primary hippocampal neuron cultures to confirm neuroprotection in a 
more physiologically relevant neuronal model.  We then explored the potential for the 
Aβ1-15 to protect or reverse (rescue) synaptic dysfunction and memory deficits resulting 
from Aβ synaptotoxicity.  Changes in synaptic plasticity were assessed by measuring 
LTP in acute mouse hippocampal slices. Furthermore, we inspected the potential for 
rescue by Aβ1-15 of LTP in APPswe hippocampal slices known to have LTP deficits.  
Lastly, we explored the effect of Aβ1-15 in different behavior paradigms on 5XFAD (FAD: 
familial Alzeimer’s disease) mice, a model expressing APPswe, APP-London and APP-
Florida mutant transgenes as well as two mutant presenilin (PS1) transgenes, which 
accumulates high levels of Aβ over an accelerated timeframe (months).  The behaviors 
examined were those related to deficits observed AD, namely contextual fear 
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conditioning, novel object recognition and elevated plus maze to examine effects on 
memory processing, recognition memory and anxiety.   
We were able to show that the Aβ1-15 protected against all measures of Aβ-
triggered neurotoxicity and neuronal dysfunction: oxidative stress, DNA fragmentation, 
apoptotic cell death, synaptotoxicity and behavioral deficits. Notably, Aβ1-15 prevented 
LTP inhibition caused by Aβ1-42 treatment and, when injected into the hippocampus was 
able to rescue memory in contextual fear conditioning as well as decrease anxiety in the 
5XFAD mice. To address preliminarily the possible molecular mechanisms underlying 
the rescue by Aβ1-15 of memory deficits in the 5XFAD, we explored signaling pathways 
known to be involved in Aβ synaptotoxicity. We observed a substantial upregulation of 
the glutamate receptor GluR2 and phosphorylated CREB in mouse hippocampi injected 
with the Aβ1-15, giving us insight into the specific actions of N-terminal fragment. 
In summary, the data show that Aβ1-15 fully protected against Aβ1-42 –induced 
cellular toxicity, synaptotoxicity and behavioral deficits. Taken together, the data support 
our hypothesis that the N-terminal fragment (Aβ1-15) is not only neuroprotective against 
acute Aβ1-42 toxicity, but also has the ability to rescue memory in 5XFAD mice, 
potentially introducing a new avenue for AD therapeutics. 
 
 
 
 
 
	 VII	
TABLE OF CONTENTS 
DEDICATION	...........................................................................................................................................................	II	
ACKNOWLEDGMENTS	......................................................................................................................................	III	
ABSTRACT	.............................................................................................................................................................	IV	
LIST OF FIGURES	................................................................................................................................................	IX	
LIST OF ABBREVIATIONS	...............................................................................................................................	XI	
CHAPTER 1	..............................................................................................................................................................	1	
INTRODUCTION	......................................................................................................................................................	1	
1. BACKGROUND	................................................................................................................................................................	2	
Alzheimer’s Disease	............................................................................................................................................................	2	
Amyloid Precursor Protein: Processing and Aβ Production	.........................................................................	3	
Beta Amyloid 1-42 (Aβ1-42)	...............................................................................................................................................	5	
Beta amyloid 1-15 (Aβ1-15)	...............................................................................................................................................	6	
Beta amyloid 10-15 (Aβ10-15, Aβcore)	........................................................................................................................	8	
Mouse Primary Hippocampal Neuron Cultures:	...............................................................................................	11	
2. OBJECTIVE AND HYPOTHESIS	..........................................................................................................................	14	
2.1. Objective	........................................................................................................................................................................	14	
2.2 Central Hypothesis	....................................................................................................................................................	15	
3. SPECIFIC AIMS	..............................................................................................................................................................	16	
3.2) SPECIFIC AIM 2.  Study the neuroprotective action of Aβ1-15 against Aβ1-42-triggered deficits in 
synaptic plasticity.	..............................................................................................................................................................	16	
3.3) SPECIFIC AIM 3.  Test the neuroprotective action of Aβ1-15 against Aβ1-42-triggered changes in 
fear memory and anxiety.	..............................................................................................................................................	17	
4.  EXPERIMENTAL APPROACH AND MODEL SYSTEMS	........................................................................	18	
APPROACHES:	.........................................................................................................................................................................	19	
5. SIGNIFICANCE	...............................................................................................................................................................	21	
CHAPTER 2	...........................................................................................................................................................	23	
CHARACTERIZATION OF THE NEUROPROTECTIVE EFFECTS OF THE N-TERMINAL Aβ  
FRAGMENT.	..........................................................................................................................................................	23	
INTRODUCTION:	.......................................................................................................................................................................	24	
A. AIM 1A. ELUCIDATE THE NEUROPROTECTIVE EFFECTS OF THE N-TERMINAL AΒ FRAGMENT 
IN VITRO	..................................................................................................................................................................................	26	
	 VIII	
A.1. Experimental Design:	............................................................................................................................................	26	
A.2. Materials and Methods:	........................................................................................................................................	31	
A.3. Results	...........................................................................................................................................................................	33	
B. AIM 1B EXAMINE THE NEUROPROTECTIVE EFFECTS OF THE N-TERMINAL AΒ FRAGMENT IN 
EX-VIVO PRIMARY HIPPOCAMPAL CELL CULTURES.	.............................................................................	38	
B.1. Experimental Design	..............................................................................................................................................	38	
B.2. Materials and Methods:	........................................................................................................................................	40	
B.3. Results	...........................................................................................................................................................................	42	
DISCUSSION	.............................................................................................................................................................................	46	
CHAPTER 3	...........................................................................................................................................................	49	
THE NEUROPROTECTIVE ACTION OF AΒ1-15 AGAINST AΒ1-42-TRIGGERED DEFICITS IN SYNAPTIC 
PLASTICITY	..........................................................................................................................................................	49	
INTRODUCTION	........................................................................................................................................................................	50	
1. EXPERIMENTAL DESIGN:	................................................................................................................................................	51	
2. MATERIALS AND METHODS	............................................................................................................................................	53	
3. RESULTS:	.............................................................................................................................................................................	55	
DISCUSSION:	............................................................................................................................................................................	60	
CHAPTER 4	...........................................................................................................................................................	63	
THE NEUROPROTECTIVE ACTION OF AΒ1-15 AGAINST AΒ1-42-TRIGGERED CHANGES IN FEAR 
MEMORY AND ANXIETY.	.................................................................................................................................	63	
INTRODUCTION:	.......................................................................................................................................................................	64	
1. EXPERIMENTAL DESIGN:	................................................................................................................................................	67	
2. MATERIALS AND METHODS	............................................................................................................................................	70	
3. RESULTS	...............................................................................................................................................................................	75	
DISCUSSION	.............................................................................................................................................................................	87	
CHAPTER 5	...........................................................................................................................................................	90	
CONCLUSIONS	....................................................................................................................................................	90	
CONCLUDING REMARKS	......................................................................................................................................................	91	
FUTURE DIRECTIONS	............................................................................................................................................................	94	
REFERENCES	......................................................................................................................................................	96		
	 IX	
LIST OF FIGURES 
 
CHAPTER 1 
Figure 1.  APP processing pathways.16……………………………………………..3 
Figure 2. Pathological effects of Aβ.19……...………………………………………4 
Figure 3. Aβ1-15 pathway. (adapted and altered)11………....……………………..6 
Figure 4. Aβ isoform pattern with (b), or without (a) γ-secretase 
inhibitor.28………………………………………………………………………………...7 
Figure 5. Amino acid sequence of full length Aβ and fragments of 
interest……………………………………………………………………………………………8   
Figure 6. Spatial organization of nAChRs.34………………………………………………….9 
 
 
CHAPTER 2   
Figure 7. Aβ toxicity timeline in α4β2 nAchR- transfected NG108-15 cells.53…………..24 
Figure 8. Fugene has the highest transfection efficiency and lowest toxicity in NG108-15 
cells.……………………………………….……………………….……………………………27 
Figure 9 Timing Experiment Schematic …………………..…………………………..……28 
Figure 10. Dosage Experiment Schematic………..…..………………………………...….29 
Figure 11. The N-terminal Aβ1-15 protects against Aβ-induced oxidative 
stress..............................................................................................................................35 
Figure 12. The N-terminal Aβ1-15 protects against Aβ-induced nuclear 
disintegration…………………………………………………………………………………...36 
Figure 13. The N-Aβ fragment and the N-Aβcore protect against Aβ1-42 -induced cell 
death in NG108-15 cell culture.  ……….…………………….……………………………...37 
Figure 14. Primary hippocampal  culture development over 6 days……………………..38 
Figure 15. The N-Aβcore and the N-Aβ fragment protect against Aβ1-42-induced 
oxidative stress in primary hippocampal neurons…………………………..…………..….42 
Figure 16. The N-Aβcore and the N-Aβ fragment protect against Aβ1-42-induced 
oxidative stress in primary hippocampal neurons……………………………...…………..43 
Figure 17. The N-Aβcore and the N-Aβ fragment are unable to protect against 
glutamate-induced oxidative stress in primary hippocampal neurons.  …………………44 
Figure 18. The N-Aβ fragment and the N-Aβcore protect against Aβ1-42 -induced cell 
death in primary hippocampal neurons……………………………………………………...45 
 
	 X	
CHAPTER 3 
Figure 19. The N-terminal Aβ1-15  has no significant effect on baseline synaptic activity 
and has to be perfused before HFS to have an effect on LTP………………….………..57 
Figure 20. Aβ1-15 enhances LTP at fM concentrations and can prevent LTP block by Aβ1-
42…………………………………………………………...………………………………….…58 
Figure 21. Aβ1-15 restores normal LTP in APPswe mouse hippocampal 
slice.…………………………………………………………………………………………..…59 
Figure 22. Proposed molecular mechanisms of Aβ synaptotoxicity.1 ……………………60 
 
 
CHAPTER 4 
Figure 23. Timeline of the pathophysiology of AD.1…………………………………....….64 
Figure 24. At 100pM, Aβ1-15 enhances memory in WT mice.2. …………………………...65 
Figure 25. Cannula placement confirmation……….……………………………………….70 
Figure 26. Figure 26. 5XFAD mice exhibit CFC deficit at 7 months of age……………..75 
Figure 27. Bilateral delivery of 500nM Aβ1-15 into the dorsal hippocampus rescues 
memory deficit in 5XFAD mice to normal WT levels.3,4………………………….…..…….76 
Figure 28.  Bilateral delivery of 500nM Aβ1-15 into the dorsal hippocampus rescues 
memory deficit in both CFC (24h later) and remote memory CFC (12d later) in 5XFAD 
mice…………………………………………………………………………………………..…77 
Figure 29.  The N-terminal core fragment Aβ10-15 rescues memory deficit in both CFC 
(24h later) and remote memory CFC (12d later) in 5XFAD mice…………………...……78 
Figure 30.  5XFAD mice exhibit hyperexploratory behavior with more time spent in the 
center of an open field…………………………………………………………………...……79 
Figure 31. Total distance traveled on days 1, 2 and 3 of NOR showed significant 
differences between WT and 5XFAD mice……………………………………...………….80 
Figure 32. No differences exhibited in novel object preference in B6.SJL and 5XFAD 
mice injected with Aβ1-15 or saline…………………………………………………..………..81 
Figure 33. No significant differences in distance travelled between groups in elevated 
plus maze………………………………………………………..……………………………..82 
Figure 34. 5XFAD mice injected with Aβ1-15 exhibit lower anxiety compared to saline 
injected 5XFAD mice…………………………………………………………………...……..83 
Figure 35. Membrane NR1 is lower in 5XFAD mice compared to WT 
counterparts…………………………………………………………………..………………..84 
Figure 36. mGluR2 levels are lower in 5XFAD mice compared to WTs with  Aβ1-15 
injection increasing mGluR2 levels in bot 5XFAD and WT mice……………………...….85 
Figure 37. pCREB levels are lower in 5XFAD mice compared to WTs with  Aβ1-15 
injection increasing pCREB in both 5XFAD and WT mice.………………...............…….86	
	 XI	
LIST OF ABBREVIATIONS 
 
Aβ-Beta Amyloid,  
AD- Alzheimer’s Disease  
FAD- Familial Alzheimer’s Disease 
APP- Amyloid Precursor Protein  
BACE- Beta site cleaving enzyme  
nAChR- nicotinic acetylcholine receptor  
ROS- reactive oxygen species 
LTP- long-term potentiation  
APLP- amyloid precursor-like protein,  
sAPP- soluble amyloid precursor protein,  
CTF- carboxy-terminal fragment,  
AICD- APP intracellular domain,  
CSF- cerebrospinal fluid,  
aCSF- artificial cerebrospinal fluid,  
WT- wild type,  
NMDA- N-methyl-D-aspartate,  
YFP- yellow fluorescent protein,  
carboxy-H2DCFDA- 5-carboxy-2’,7’-dichlorodihydrofluorescein. 
 
  
	 1	
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
Introduction 
 
	 2	
1. BACKGROUND 
Alzheimer’s Disease 
 
Alzheimer’s disease (AD) is a neurodegenerative disease that currently affects 5.2 
million people in the United States, making it the most common form of dementia.5 Dr. 
Alois Alzheimer first described AD (initially known as presenile dementia of the 
Alzheimer-type) in 1907, after the postmortem examination of a brain of a middle-aged 
insane asylum patient. The patient’s behavioral symptoms at the asylum were described 
as progressive memory loss, confusion, personality changes, as well as the eventual 
loss of motor skills: all classical AD symptoms.  Dr. Alzheimer described an atrophied 
brain that, when silver stained, showed abnormal aggregation of plaques and fibrils in 
the area where neurons had died.6 We now know these to be the two pathological 
hallmarks of AD: beta amyloid plaques, and tau tangles, respectively.   
 The amyloid cascade hypothesis refers to the conjecture that amyloid 
accumulation leads to the pathogenesis of AD.7 This hypothesis was developed after 
many studies showed that AD brains had significantly higher amounts of soluble Aβ 
compared to normal brains.  More recently, however, there has been a large amount of 
evidence that alludes to Aβ being a neuromodulator.8 At low levels, Aβ modulates 
neuroplasticity and memory, demonstrating an important physiological role that makes 
targeting Aβ for treatment of AD a more complicated issue.9 It had also been 
demonstrated that processing of APP by different combinations of secretases will 
produce Aβ peptides of different lengths.10 Of particular interest to our lab is the N-
terminal fragment Aβ1-15.  While the Aβ1-42 fragment has been shown to have toxic 
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effects at high concentrations,11 Aβ1-15 has not shown any signs of toxicity at the same 
concentrations. This leads us to investigate possible neuroprotective effects of the N-
terminal fragment. 
Amyloid Precursor Protein: Processing and Aβ Production 
 
Amyloid precursor protein (APP) is a membrane spanning protein that belongs to a 
family encoded by three mammalian genes. 12,13 APP physiological functions are poorly 
defined and APP knockout mice have shown almost normal phenotypes, most likely 
because of compensation by amyloid precursor-like proteins 1 and 2 (APLP1 and 
APLP2).13 It has been suggested that APP plays a role in everything from 
transmembrane signal transduction, synaptogenesis, and cell adhesion to neuronal 
protein trafficking along axons.14 A recent study has shown that increased APP tyrosine 
phosphorylation in AD neurons 
alters trafficking of APP, suggesting 
APP tyrosine phosphorylation can 
be a therapeutic target for AD, but 
more in-depth studies are required.15 
In contrast, APP processing has 
been widely studied because of its 
central role in the production of Aβ 
and the pathology of AD.  APP goes 
through a regulated, sequential 
cleavage by three different 
Figure 1.  APP processing pathways.17 a. 
Nonamyloidgenic pathway-APP is cleaved 
with in the Aβ sequence by α-secrestase releasing 
the APPsα  ectodomain followed by γ - secretase 
cleavage releasing the p3 fragment. b. Amyloidgenic 
pathway- β-secretase cleaves APP releasing APPsβ 
followed by γ-secretase cleavage releasing Aβ. 
	 4	
secretases: α-secretase, β-secretase, and γ-secretase.   
 There are two well established pathways by which APP is processed: the 
amyloidogenic pathway and the non amyloidogenic pathway (Fig.1).16 The non 
amyloidegenic pathway is the predominant pathway in which APP is cleaved by α and 
then γ- secretases.17,12,18  The α-secretase cleavage releases soluble APPα (sAPPα), 
shown to have roles in cell migration, differentiation, and adhesion.17 The γ-secretase 
then cleaves the remaining carboxy-terminal fragment α (CTFα) resulting in a P3 
fragment and releases an APP intracellular domain (AICD).  The AICD is known to be a 
transcription regulator of: Neprilysin (a Aβ 
degrading enzyme), BACE1 (a β-secretase), 
and APP.17,18  
 Aβ production is achieved via the 
amyloidogenic pathway.  Initially, β-secretase 
cleaves APP into sAPPβ, a fragment involved 
in cell viability, differentiation, axonal 
outgrowth and microglia activation, and a C-
terminal fragment, CTFβ.  The CTFβ is then 
cleaved by γ-secretase at multiple possible 
cleavage sites resulting in an Aβ fragment 38-
42 amino acids in length, with the majority 
being Aβ1-40 and Aβ1-42.17,13,19 
 
Figure 2. Pathological effects of Aβ .La 
Ferla Aβ aggregates into oligomers mediating 
pathological events such as the facilitation 
of tau hyper-phosphorylation, proteasome 
and mitochondrial disruption, calcium and 
synaptic dysfunction as well as contribute to 
ROS. 
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Beta Amyloid 1-42 (Aβ1-42) 
 
Aβ1-42 has long been linked to AD pathology.  The classic Aβ cascade hypothesis is 
based on the fact that Aβ aggregates into oligomeric fibrils and then into plaques. While 
the plaques are one of the hallmarks of AD, it is the Aβ oligomers that start a 
pathological cascade that leads to neurodegeneration.20,21,22 Aβ can be generated 
wherever APP resides with β- and γ-secretases.  Aβ generation occurs on the cell 
membrane and is released extracellularly, but can also occur intracellularly, in the 
endoplasmic reticulum, Golgi, endosomal, lysosomal, and mitochondrial 
membranes.14,21,23 Aβ is predominantly released at synaptic sites. 
 Aβ1-42 is more hydrophobic than Aβ1-40 and therefore its oligomers are more likely 
to aggregate and cause a myriad of disruptive actions before forming the Aβ plaques 
seen in AD brain.22 The overproduction of Aβ oligomers not only leads to amyloid 
plaques, but has also been shown to cause excitotoxicity, oxidative stress, 
neurotransmitter deficits, synaptic dysfunction, activation of apoptosis, and neuronal cell 
death (Fig.2).21,22,24 A balance of Aβ production and clearance is imperative to avoid 
pathogenesis.  Production and clearance of Aβ have been studied using metabolic 
labeling and it was apparent that clearance of Aβ in the central nervous system of AD 
patients was impaired.25  
 While Aβ has generally been accepted as a toxic peptide found in aged or AD 
brains, the discovery of soluble Aβ at very low concentrations in normal brain suggests 
that it has a physiological modulatory function.14,9,26,27 While nanomolar levels of Aβ 
block LTP, picomolar levels enhance synaptic plasticity in electrophysiological 
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experiments, and memory in Morris water maze and contextual fear conditioning 
experiments.9,7,27 Another study demonstrated similar results with low doses of Aβ 
enhancing LTP and memory in both T-maze foot shock avoidance as well as object 
recognition.26 At low picomolar levels, Aβ was shown to be necessary for normal LTP 
and memory, as blocking Aβ1-42 blocked LTP and caused learning deficits.8,27 Taken 
together, this makes targeting of Aβ for AD treatment a complicated endeavor and 
alternate treatment approaches are needed. 
 
Beta amyloid 1-15 (Aβ1-15) 
 
Recently, an alternative pathway was identified in which Aβ1-15 is produced.  This 
alternative pathway involves sequential cleavage of APP by β- and α-secretases 
Figure 3. Aβ 1-15 pathway.  Aβ1-15 is produced by the cleavage of APP by β- 
and α-secretases fol lowed by a carboxypeptidase.  
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followed by a carboxypeptidase (Fig.3).10,28 This pathway was demonstrated by treating 
a cell culture model that secreted soluble APP and Aβ with γ-secretase inhibitors, which 
eliminated secretion of all Aβ isoforms larger than Aβ1-16 (Fig. 4).10,29 Three different 
studies in dogs, nonhuman primates, and humans confirmed the same result upon 
testing CSF after treatment with the γ-secretase inhibitor.  The studies showed Aβ1-15/16 
increased up to 9 hours in dogs and humans and 48 hours in nonhuman primates after 
treatment.30,31,32 
 Aβ1-15 is also increased in cerebrospinal fluid (CSF) of AD patients suggesting an 
alteration from the amyloidogenic pathway during pathogenesis.10 The N-terminal 
fragment is hydrophilic and is extremely unlikely to contribute to aggregation of Aβ and 
Figure 4. Aβ  isoform pattern without (a) or with (b) γ-secretase inhibitor.28 γ-
secretase inhibitors eliminate secretion of all Aβ isoforms larger than Aβ1-16	
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subsequent toxicity. Recent studies in our laboratory have demonstrated that Aβ1-15 is a 
highly potent activator of α7 nAChRs, can enhance long term potentiation in 
hippocampal slices, can enhance memory of wild-type mice in contextual fear 
conditioning tests, and can rescue APPswe (an AD mouse model) LTP deficits.2 
Considering Aβ1-15 is endogenous in CSF, is nontoxic, and highly active via nAChRs, 
Aβ1-15 is a very attractive and promising peptide to test for neuroprotective effects 
against Aβ1-42 toxicity.  
 
Beta amyloid 10-15 (Aβ10-15, Aβcore) 
 
The 10-15 sequence of Aβ1-15 (Fig. 5) was found to be accountable for the activity of 
both the N-terminal Aβ and Aβ1-42 via calcium responses through its agonist-like action 
on nAChRs.2 Whilst this shorter peptide is not produced endogenously, it has become a 
focal point of the current study because of the potential for development into a novel 
therapeutic for AD as a peptidomimetic.  A short peptide and/or modified derivative 
would be much easier to develop as a drug that could potentially cross the blood-brain 
barrier (BBB) for non-invasive delivery to the area of interest, as it is currently unknown 
as to whether the Aβ10-15 can cross the BBB. An alternative means for delivery would be 
application via the intranasal route. 
Figure 5. Amino acid sequence of full length Aβ  and fragments of interest.  Aβ1-42 whole 
sequence shown with Aβ1-15 in blue and green and Aβ10-15 in green. 
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AD and Aβ target receptors 
Cholinergic dysfunction is a characteristic of AD pathology.33,34 Acetylcholine and the 
cholinergic system play a pivotal role in synaptic plasticity and cognition. Changes and 
defects due to the dysfunction of the cholinergic system include changes in: 
acetylcholine synthesis, neurotropic factors, vesicular transporters, and muscarinic and 
nicotinic receptors.33–35  
 Nicotinic acetylcholine 
receptors (nAChRs) are 
pentameric ligand-gated ion 
channels that are widespread in 
the central nervous system (Fig. 
6).36 They are activated by 
acetylcholine and nicotine and are 
made up of α- and/or β-subunits 
with the three most abundant 
subtypes in the brain being α7 
receptors, α4β2 receptors, and 
α3β4 receptors.35  
       Aβ1-42 has a very high binding affinity to nicotinic acetylcholine receptors (nAChRs), 
resulting an agonist-like action through both α7 and α4β2 nAChRs.37,38,39.  Many studies 
have shown a link between nAChRs and AD, with the most vulnerable neurons being 
the ones that express these receptors.35 Furthermore, our lab has demonstrated that 
Figure 6. Spatial organization of nAChRs.34 Aβ1-42 has 
a very high binding affinity to nAChRs with agonist-like 
action through both α7 and α4β2 nAChRs. A, overview 
of the pentameric arrangement of the individual subunits 
of the nAChR in the membrane. B, side view of the 
atomic structure of the nAChR across the membrane 
(ECD: extracellular domain; TMD, transmembrane 
domain, ICD, intracellular domain. C, typical 
stoichiometric arrangement of individual subunits for the 
α7 and α4β2 nAChRs.   
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the presence of α4β2 nAChRs sensitizes NG108-15 model neuronal cells to the toxic 
effects of Aβ1-42, further confirming this point.39 Calcium imaging performed in our lab 
has also confirmed that both Aβ1-42 and Aβ1-15 are highly potent activators of α7 nAChRs 
with Aβ1-15 having a significantly higher calcium response.2 The nAChRs are a potential 
target for AD therapy because they play an important role in AD pathology with regard 
to Aβ binding.33,35,40 
 Aβ has several other putative target receptors, including cellular prion protein 
(PrPc), amylin receptors and metabotropic glutamate receptors, and p75 neurotrophin 
receptors, among others. Aβ binding to these receptors leads to changes in 
conformation and expression, and alterations in signaling pathways.41,42 PrPc appears 
to be the primary receptor mediating toxicity with elevated Aβ levels.  It is a glycoprotein 
that plays a pivotal role in synaptic structure and function.  Aβ oligomers bind to cells 
expressing PrPc.  PrPc has also been observed in Aβ plaques in brains of transgenic 
mice.41–43   
 
NG108-15 cells 
Our primary in vitro model is the NG108-15 hybrid rodent neuroblastoma cell line 
(mouse N18TG2 neuroblastoma cells fused with rat C6-BU-1 glioma cells).  This cell 
line is able to form presynaptic-like varicosities after differentiation, which can form 
synapses with muscle cells, release acetylcholine, and have functional IP3- and 
ryanodine-sensitive calcium stores.44–46 The NG108-15 cell line does not express 
nAChRs. 
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While Aβ accumulation in AD patients happens over many years, the simplified 
model systems used in this study allowed us to investigate the effects of Aβ through 
nAChRs over a shortened time frame. The ability to transfect the nAChRs into our 
model systems also allowed us to look at specific cells in culture to help distinguish 
responses caused by interaction of Aβ with nAChRs, as opposed to general Aβ toxicity, 
without transcriptional regulation. These model systems also allowed us to control the 
concentration of Aβ from low picomolar concentration, wherein Aβ acts as a 
neuromodulator, to nanomolar concentrations or higher causing dysfunction and 
eventual cell death. This simplified model allowed for direct investigation of Aβ1-15 
neuroprotection that could be quantified without the presence of secondary protective 
measures as found in vivo.   
The ability to study Aβ1-15 neuroprotection in a simple cell culture model provided a 
framework for advancing the study into hippocampal neuron cultures and, subsequently, 
into APPswe mouse models, with the long-term goal of evaluating Aβ1-15 as a novel 
avenue for AD treatment. 
 
Mouse Primary Hippocampal Neuron Cultures:  
 
While in vitro cultures have been fundamental to the advancement of our understanding 
of the function of the nervous system, they have many limitations.  Usually, the cell lines 
are derived from tumor cells to overcome the biggest limitation with primary neurons 
being post-mitotic and thus unable to divide (grow).  Furthermore, these secondary cell 
lines, while useful as models, do not fully recapitulate the development and physiology 
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of the primary cells from which they are derived.47,48 Primary cells solve this problem. 
Their primary advantage is that they replicate the properties of neuronal cells in vivo. 
Primary hippocampal neurons are able to extend axons and dendrites by a sequence 
typical of developmental events in vivo and are even able to form physiologically active 
synaptic contacts.48,49 Their limitations are the practical issue of the typically small 
numbers of neurons obtained in cell culture preparations, even from several animals, 
and the restricted developmental stage from which viable cultures are usually prepared. 
 
 
Alzheimer’s Disease Pathology Mouse Models  
Genetically modified mouse models are vital for uncovering the molecular mechanisms 
involved in AD pathology. Rodent models are appropriate due to functional 
modifications that mimic human pathology in the hippocampus and entorhinal cortex. 
Currently, a large number of different mouse models exist, varying as to the transgenes 
expressed for induction of AD pathology (primarily familial Alzheimer’s disease (FAD) 
genes), specifically in regard to the timing and extent accumulation of Aβ.50 
Furthermore, behavioral phenotypes that present in accordance with insertion of FAD 
genes are relevant in view of the phenotypic similarity to human disease. Cognitive 
assays, performed in parallel to corresponding protein extractions from different cellular 
compartments to look at changes in protein levels for molecules of interest, can give us 
insight to the correlation of functional and molecular changes induced by different 
treatments. 
	 13	
              Of note, there are only a limited number of other animal models for AD, most of 
which are either impractical or not readily available. Chief among these other models 
are canine and non-human primate dementia. The aged canine model for AD does have 
notable advantages, specifically similar late-onset pathology (ie. with aging alone), 
memory, cognitive and recognition deficits, and anxiety as that founds for humans 51	 
As useful as the animal models are, there are limitations. The biggest limitation 
for the basic APP mouse models is that they are only able to produce amyloid plaques 
and, to a limited degrees, loss of neurons, but not neurofibrillary tangles that have a 
significant contribution to the pathogenesis of AD.  It is also stressful for the animals to 
be surgically cannulated or injected.  Another disadvantage is that breeding and 
housing of animals until the appropriate age proves to be costly.  Despite these 
limitations, use of APP animal models is imperative for the uncovering of molecular 
changes that occur with Aβ accumulation in accordance with behavior in response to 
different treatments during different stages of pathophysiology of disease.  
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2. OBJECTIVE AND HYPOTHESIS 
2.1. Objective 
 
Beta amyloid (Aβ) is a key contributor to the pathogenesis of Alzheimer’s disease (AD).  
It is produced via the sequential cleavage of the amyloid precursor protein (APP) by the 
β-site APP cleaving enzyme (BACE1 or β-secretase), followed by γ-secretase.20 This 
processing sequence is known as the amyloidogenic pathway and results in the 
production of amyloid peptides 38-42 amino acids in length, owing to the variability in γ-
secretase cleavage, with Aβ1-42 being the dominant form present in neuritic plaques in 
the brains of individuals with AD.14 Aβ1-42 is produced in neurons and then released at 
synaptic sites. In normal brain, Aβ is present at relatively low levels (pM) in an 
oligomeric form and has been proposed to have a neuromodulatory role. During the 
onset of AD, excess Aβ accumulates to high nM to µM levels, most likely as the result of 
impaired clearance, and this pronounced increase correlates with disease progression.  
When left unchecked, Aβ appears to obstruct normal signaling and accumulate into 
amyloid plaques, eventually causing neuronal cell death.52 
There is an alternative pathway by which APP is cleaved yielding N-terminal Aβ 
fragments 15-16 amino acids in length. Specifically, Aβ1-15 is produced by the sequential 
cleavage of APP by β- and α-secretases, respectively, followed by carboxypeptidase.10 
Our lab has recently shown Aβ1-15 to be highly active toward the nicotinic acetylcholine 
receptor (nAChR), as assessed by changes in neuronal calcium, and to modulate 
synaptic plasticity and contextual fear memory3. We have also shown that the presence 
of the high-affinity α4β2 nAChRs sensitizes neurons to the neurotoxic action of Aβ1-42.39 
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In contrast, our most recent studies have shown the N-terminal Aβ fragment to be non-
toxic.  Due to its high activity and non-toxicity, we proposed therefore that Aβ1-15 could 
have a neuroprotective action against Aβ1-42-triggered neurotoxicity.  The objective of 
this study was to address this possibility in various AD models: in vitro, ex-vivo, and in 
vivo to provide a potential new avenue for the development of novel AD therapies. 
 
2.2 Central Hypothesis 
 
The N-terminal Aβ fragment (Aβ1-15) and the core hexapeptide fragment (Aβ10-15) are 
neuroprotective against toxic full-length Aβ (Aβ1-42). To test this hypothesis, the effect of 
treatment with Aβ1-15 on Aβ1-42–triggered neurotoxicity will be evaluated using in vitro, 
ex-vivo and in vivo approaches as follows. 
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3. SPECIFIC AIMS 
 
3.1) SPECIFIC AIM 1. Characterize the neuroprotective effects of the N-terminal 
Aβ fragment against Aβ cytotoxicity. 
A. Elucidate the neuroprotective effects of the N-terminal Aβ fragment in vitro . 
 
Specific Rationale: Sustained exposure of NG108-15 cells expressing nAChRs to nM 
levels of Aβ1-42 causes increased reactive oxygen species and cell death.  Aβ1-15 is 
strongly activating through nAChRs with no toxic effects. We hypothesize that Aβ1-15 is 
neuroprotective against Aβ1-42 toxicity. 
 
B. Examine the neuroprotective effects of the N-terminal Aβ fragment in ex-vivo 
primary hippocampal cell cultures. 
 
Specific Rationale: It is important to compare in vitro results with ex-vivo hippocampal 
neuron cultures where the cells are more physiologically accurate and relevant to AD.  
Ex-vivo cultures recapitulate neuronal development and characteristics found in vivo. 
 
3.2) SPECIFIC AIM 2.  Study the neuroprotective action of Aβ1-15 against Aβ1-42-
triggered deficits in synaptic plasticity. 
 
Specific Rationale: Hormetic effects of Aβ1-42 have clearly been shown wherein Aβ1-42 
enhances synaptic plasticity at low picomolar levels and blocks LTP at high nanomolar 
levels.7 This has been supported via confocal calcium imaging in our lab, confirming the 
neuromodulatory role of Aβ1-42.2 Moreover, Aβ1-15 shows even higher action via α7 
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nAChRs in calcium imaging experiments also supporting that this N-terminal fragment 
has neuromodulatory actions.2 Taken together with the non-toxicity of this fragment, this 
led us to hypothesize that Aβ1-15 will enhance LTP, and protect the synapses from Aβ1-42 
toxicity.  We also hypothesize that Aβ1-15 rescues LTP deficits in APPswe mice. 
 
3.3) SPECIFIC AIM 3.  Test the neuroprotective action of Aβ1-15 against Aβ1-42-
triggered changes in fear memory and anxiety. 
 
Specific Rationale: We have demonstrated that Aβ1-15 has neuroprotective effects in 
several models of Aβ1-42 toxicity (in-vitro NG108-15 cells, and ex-vivo primary 
hippocampal cell cultures and acute slices for LTP). We have also shown that Aβ1-15 is 
able to enhance CFC in wild-type mice.  Our goal in this Aim was to address the 
relevance of the neuroprotective action of Aβ1-15 by demonstrating behavioral benefits in 
an intact Alzheimer’s mouse model. 
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4.  EXPERIMENTAL APPROACH AND MODEL SYSTEMS 
 
Overall design: We exploited several model systems (NG108-15 cells, primary 
hippocampal cell cultures, and WT and AD mouse model) to investigate the 
neuroprotective effect of the Aβ1-15 N-terminal fragment against Aβ1-42 toxicity. 
Relevance: The effect of neuroprotection by Aβ1-15 from Aβ1-42 toxicity provides a better 
understanding of how disruption by Aβ1-15 can halt cell death and protect the cells. This 
may lead to new avenues for AD therapies. 
Model systems: This study focused on three model systems: in vitro NG108-15 rodent 
hybrid neuroblastoma cells, ex vivo mouse hippocampal cell cultures, and in vivo WT, 
APPswe, and 5XFAD mouse models (further discussed in their respective sections). α4 
& β2 nAChR plasmids were utilized to examine nAChR involvement in neuroprotection 
in NG108-15 cells.  This allowed for a more direct understanding of Aβ1-42 toxicity 
disrupted by Aβ1-15 via nAChRs. 
Aβ:  Preparation of both Aβ1-42, Aβ1-15, and Aβ10-15 was begun by reconstitution in 
double distilled water, bath sonication for 20 minutes, and then dilution to the working 
concentration in working solution as previously described.2,39 All Aβ peptides were 
purchased from American Peptide and Peptide 2.0. 
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Approaches:  
 
Reactive oxygen species (ROS): ROS assay was used to assess ROS production due 
to Aβ1-42 and/or Aβ1-15 action via the α4β2 receptors. The Image iT live Reactive Oxygen 
Species (ROS) Detection kit (Invitrogen) was used to detect nonspecific ROS.  5-
Carboxy-2’,7’-dichlorodihydrofluorescein (carboxy-H2DCFDA) enters the live cells and is 
deacetylated by non-specific esterases in the cell.  Intracellular ROS oxidizes the 
reduced fluorescein, emitting green fluorescence visualized by fluorescence 
microscopy. 
HOECHST staining: The blue fluorescent HOECHST 3342 dye (Invitrogen) is a nucleic 
acid stain that is highly cell-permeable and sensitive to chromatin conformation. 
HOECHST 3342 dye is visualized by fluorescence microscopy. 
Electrophysiology: Basic hippocampal long-term potentiation (LTP) was performed as 
described in Lawrence et al., 2014.2 Hippocampal slices were stimulated via the 
Schaffer collaterals and field potentials recorded from the CA1 pyramidal cells. Data are 
derived as slope values from the field potentials and are normalized to baseline. 
Behavioral experiments: Contextual fear conditioning (CFC), Novel Object recognition 
(NOR) and Elevated Plus Maze (EPM) paradigms were employed to test mouse 
learning and memory.  Single-trial CFC was performed as described by Sherrin et al., 
2010 and Lawrence et al., 2014 in collaboration with Dr. Cedomir Todorovic and Dr. 
Tessi Sherrin.2,53. 
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Western Blot: After behavior experiments, hippocampi were extracted, lysed and lysates 
collected and spun down to extract membrane vs. cytosolic proteins for Western 
(immunoblot) analysis.   
Data and statistical analysis: Treatment and units were randomized as to order 
for all assays and experiments. Biological replicates were based on independent 
samples (n). Each experiment was repeated four times.  Paired Student’s t-test or one-
way ANOVA with Bonferroni multiple comparison post-hoc test were performed for 
statistical analysis of different treatment groups for ROS, TUNEL, and Western blots 
associated with comparison of cell viability due to different treatment groups.  
Electrophysiology long-term potentiation experiments and behavior tests were also 
analyzed using one-way ANOVA with the Bonferroni posthoc test. All quantitative 
results are presented as boxplots (5-95% confidence intervals), where appropriate, or 
means ± SEM. All data were analyzed and graphed using Prism (Graphpad). P-values 
<0.05 were considered the minimum for significance (as rejection of the null 
hypothesis). Refer forward to appropriate chapters for detailed experimental design and 
data acquisition 
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5. SIGNIFICANCE  
 
Approximately 5.2 million people in the United States are affected by Alzheimer’s 
disease, and that number is expected to rise with increasing longevity.5 Current FDA-
approved drugs for AD treatment fall under two categories: Cholinesterase inhibitors 
(Donepezil and Galantamine), and NMDA receptor antagonists (Memantine).54,55 These 
drugs generally treat the symptoms of AD by regulating neurotransmitters in the brain 
and there is an indication that Memantine may slow the progression of symptoms, but 
none is unable to change AD pathology.  Therefore, it is important to examine other 
avenues for the development of AD therapies. 
 The amyloid hypothesis is based on the idea that the driving force in AD is the 
accumulation of Aβ42 resulting from impaired clearance with age.  Therapeutic targets 
based on this hypothesis could therefore be based on APP processing pathways. It 
would be possible to differentially target the APP processing pathways by inhibiting the 
amyloidogenic pathway via targeting of β- and γ-secretases or by enhancing the non-
amyloidogenic pathway by targeting and promoting α-secretase activity.  The problem 
with these strategies is that the secretases have a myriad of substrates and targeting 
them would cause too many negative symptoms.54,56  
 Portelius et al. (2011) demonstrated an alternative APP processing pathway that 
produces a variety of short Aβ peptides.10 The Aβ1-15 N-terminal fragment is of particular 
interest to this project because it is a short, hydrophilic peptide that does not 
aggregate3.  It has been previously shown that Aβ has neuromodulatory effects at low 
levels and only becomes toxic at high levels.8,9,55 Armed with this knowledge, our lab set 
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out to explore the possibility that Aβ1-15 could also have neuromodulatory effects and 
found that it indeed was highly potent and more effective than full-length Aβ in agonist-
like activity via nAChRs3.  Pilot studies in a neuroblastoma cell line also showed that the 
Aβ1-15 was nontoxic at the same concentrations that Aβ42 showed clear toxicity leading 
us to the possibility that this N-terminal fragment could be neuroprotective. This study 
highlights the potential for development of a novel therapeutic for AD that would target 
the amyloid hypothesis by using endogenous peptides. 
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CHAPTER 2 
CHARACTERIZATION OF THE NEUROPROTECTIVE 
EFFECTS OF THE N-TERMINAL Aβ  FRAGMENT. 
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Introduction: 
 
According to the amyloid hypothesis, the primary force driving AD is the prodromal 
accumulation of Aβ42 in the brain. At picomolar levels, Aβ has a neuromodulatory role, 
but at high levels (micromolar) it becomes toxic leading to oxidative stress, cellular 
toxicity, synaptic dysfunction, and cognitive impairment.39,21,9  Previously published work 
from our lab has shown that the presence of nicotinic acetylcholine receptors, 
specifically the α4β2 nAChRs, sensitize the cell to toxic effects of Aβ in such a way that 
disrupts calcium homeostasis, neuronal integrity, and mitochondrial function at 
picomolar to nanomolar levels.39 In accordance with these studies, our lab has 
established an Aβ toxicity timeline representing key changes that occur in a 
neuroblastoma cell line transfected with α4β2 nAchRs  (Fig. 7).57 We are able to test 
Figure 7.	Aβ  toxicity timeline in α4β2 nAchR- transfected NG108-15 cells.53 The effects 
of Aβ toxicity on NG108-15 cells are seen as early as day 1 with increases in oxidative stress 
and altered mitochondrial dynamics followed by nuclear disintegration and altered receptor 
regulation on day 3 and apoptosis beginning on day 4.	
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peptides and their ability to disrupt this toxicity at different time points corresponding to 
specific changes, or even to rescue from toxicity post treatment with Aβ42.  
In this study, we explored the neuroprotective potential of N-terminal Aβ peptides 
against the toxic effects of Aβ42.  We utilized an ROS assay to measure oxidative stress 
and examined nuclear disintegration as an early indicator of apoptosis to investigate the 
impact of different doses of Aβ1-15 against Aβ42 toxicity in the NG108-15 neuroblastoma 
model neuronal cell line.  We also examined different treatment timing to explore how 
effective the N-terminal Aβ peptides are at reducing ROS and nuclear disintegration 
after Aβ42 toxicity pathways are already activated.  To determine whether the effects 
were long lasting, we also measured cell survival over one week of treatment.   
We followed these experiments by tests in the more physiologically relevant 
primary hippocampal neuron culture system to confirm the neuroprotective effect of the 
N-terminal Aβ peptides.  In the primary cultures, we can explore neuroprotection against 
Aβ toxicity via all receptors with which Aβ can interact. 
          Aβ1-15 is postulated to be neuroprotective due to being still highly active via 
nAChRs, and as a short, hydrophilic peptide that is unlikely to aggregate.2 The fact that 
it is an endogenous peptide also makes it an appealing molecule to explore and 
possibly develop as a novel therapeutic for AD. 		
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A. Aim 1a. ELUCIDATE THE NEUROPROTECTIVE EFFECTS OF THE N-
TERMINAL Aβ FRAGMENT IN VITRO	
A.1. Experimental Design:  
 
Model: Use of the differentiated NG108-15 hybrid neuroblastoma cell culture system in 
an Aβ neurotoxicity model has been well established.39 We utilized this model to study 
the effects of Aβ1-15 on cells exposed to toxic concentrations of Aβ1-42 over three to five 
days using multiple methods, including ROS assay and HOECHST staining (see Fig. 7). 
The production of ROS is an indicator of oxidative stress, whereas the HOECHST 
staining permits assessment of the integrity of individual nuclei. The production of ROS 
is a general measure of cellular stress, while nuclear disintegration is a more direct 
measure of toxicity indicating the start of apoptosis. Cell survival was assessed with 
simple random cell counts over 7 days in both α4β2 nAChR-transfected and mock-
transfected cells. 
Transfection conditions: Before any experiments were performed, we had to identify the 
best-suited transfection reagent that caused the least toxicity in culture with the 
maximum transfection rate (“efficiency”). We did this by performing 
immunocytochemistry using α4 nAChR subunit primary antibody to look at both α4*-
nAChR immuno-positive cells (% immune positive) and signal intensity measured via 
ImageJ.  We also utilized a HOECHST stain to look at toxicity of the reagents via 
nuclear disintegration.  For transfection reagents, we tested both FuGENE (Promega), 
and NeuroMag (OZ Biosciences) with 2uL DNA:5ul Neuromag or 2uL DNA:6uL 
Neuromag with the following results: 
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      Figure 8. Fugene has the highest transfection efficiency and lowest toxicity in NG108-15 
cells. Transfection efficiency and toxicity confirmed via α 4-immunocytochemistry and 
Hoechst staining. Transfection conditions tested were: FuGENE and NeuroMag with 2uL 
DNA:5ul Neuromag or 2uL DNA:6uL Neuromag. A, Respresentative micrographs of each 
transfection condition. B, Signal intensity measured via imageJ. C, Percent immune-positive 
cells calculated via raw cell counts of immunopositive cells compared to total cells. D, Percent 
nuclear disintegration calculated by counting fragmented nuclei utilizing Hoechst stain. 
A 
B 
C D 
	 28	
Although NeuroMag 2:6 produced signal intensity and α4-nAChR 
immunopositivity that matched that found for FuGENE, the Neuromag 2:6-transfected 
cultures displayed higher levels of baseline nuclear disintegration.  This confirmed that 
FuGENE would be the most appropriate for transfecting the α4 and β2 nAChR subunit 
pcDNA vectors. 
Timing and Dosage: We performed 2 sets of three different experiments looking at Aβ1-
15 treatment timing as well as different Aβ1-15 dosage, to investigate the effect of Aβ1-15 
on Aβ1-42 toxicity. All experiments had the following treatments: Untreated, 100nM Aβ1-
42, Aβ1-15, combination 100nM Aβ1-42 and (different concentrations) Aβ1-15, 50µM N-
acetylcysteine (NAC), and combination 100nM Aβ1-42 with 50µM NAC. NAC is used as a 
generic antioxidant.  It is a precursor to the formation of glutathione, an antioxidant that 
can reduce free radicals.  
 
 
 
 
 
 
 
 
 
 
Figure 9. Timing Experiment Schematic. Different timing of 100nM Aβ1-
15  (Priming- 1 day prior to Aβ1-42, Cotreatment and Reversal- 1 day post 
Aβ1-42 treatment) will be tested in combination with 100nM Aβ1-42 to 
investigate timing effect of Aβ1-15 neuroprotection against Aβ1-42 toxicity. 
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1. The combination treatment timings were varied for each experiment (Fig. 9).  
- To explore potential competition at the level of the target receptors, the combination 
treatments were done at the same time.  
- For priming experiments to examine the impact of pretreatment with the fragment, 
Aβ1-15 or NAC was added one day before Aβ1-42,  
- For reversal/rescue experiments the Aβ1-15 and NAC combination with Aβ1-42 was 
added one day after Aβ1-42.   
2. Dosage experiments were carried out to examine the neuroprotective potency of the 
N-terminal fragment Aβ1-15 on Aβ1-42 toxicity.  We explored 3 different concentrations: 
10nM, 100nM, and 500nM Aβ1-15 on 100nM Aβ1-42 (Fig. 10), based on previous 
experiments examining the potency of the Aβ peptides in neuromodulation. 
 
 
 
 
 
 
 
 
 
 
Figure 10. Dosage Experiment Schematic. Different dosages of Aβ1-15 
(10, 100 and 500nM) will be tested in combination with 100nM Aβ1-42 to 
investigate potency of Aβ1-15 neuroprotection against Aβ1-42 toxicity. 
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ROS assay and HOESCHT staining were performed on the fourth day to assess 
the effects of Aβ1-15 on Aβ1-42 toxicity and were compared to untreated controls and NAC 
treatment. This approach directly tested the neuroprotective properties of the N-terminal 
Aβ fragment. The ROS assay showed general ROS, which parallels the oxidative stress 
the cells are incurring due to Aβ1-42 toxicity.  The Hoechst stain, on the other hand, 
identifies cells that are in the early stages of apoptosis, because it directly stains DNA, 
with fragmented nuclei indicating progression toward cell death. This allowed us to 
investigate different stages of the compromise of cell integrity due to the toxicity of Aβ1-
42. Stains were visualized on the Olympus IX71 epifluorescence microscope via a 
Macrofire camera. 
In addition, a cell survival experiment was performed to examine the length of 
time the cells will survive the different treatments and to observe whether the 
neuroprotective effect of Aβ1-15 is sustained for over a week.  
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A.2. Materials and Methods:  	
 
Cell Culture: 
NG108-15 cells were first plated on poly-L-lysine-coated or Cell-Tak-coated coverslips 
in 35mm dishes in 15% fetal bovine serum (FBS) with Dulbecco’s modified Eagle’s 
medium (DMEM).  After allowing for the cells to attach (approximately 2 hours), the 
media was changed to DMEM with 1% FBS and 1mM dibutyryl cyclic AMP 
(differentiation media) to induce neuronal differentiation.  
Forty-eight hours after differentiation, when the cells had developed neurites and 
varicosities, mouse α4 and β2 nAChR sequences in pcDNA 3.1 vectors were 
transfected into the cells at a 1:4 ratio using FuGENE reagent. Mock transfection was 
carried out using FuGENE reagent with no plasmid. Expression of nAChRs was verified 
by α4-nAChR immunocytochemistry up to one week post-transfection. 
 
Treatments: 
Treatments began 72 hours after transfection and consisted of the aforementioned 
treatment groups (Figs. 9&10). Cell culture media was changed every day with the 
appropriate treatments to keep concentrations of treatments consistent throughout the 
treatment days.  Treatments lasted for 3 days with ROS assay and Hoechst staining 
performed on the 4th day.   
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ROS and HOECHST staining: 
The Image iT live Reactive Oxygen Species Detection kit (Life Technologies) was 
utilized with Hoechst staining as described under the experimental approach.  The 
assay was performed in accordance with the manufacturer’s protocol.  After the last day 
of treatment the cells were washed with HBSS and then incubated with Component A 
(carboxy-H2DCFDA) at 37°C for 30 minutes.  Component B (HOECHST stain) was 
added in the last 5 minutes of incubation at 2µg/mL. Finally, cells were washed with 
HBSS and visualized via Olympus IX71 epifluorescence microscope linked to a 
Macrofire camera at 495 nm excitation/529 nm emission for ROS and 350 nm 
excitation/461 nm emission for HOECHST stain.  
Data were graphed as percent ROS positive cells by doing simple cell counts 
from randomly chosen fields of view with a minimum sample size of four for each test. 
Nuclear disintegration was similarly quantified. 
 
Cell Survival: 
We also performed a 7-day cell survival assay under previously outlined treatments, to 
better elucidate the toxicity/neuroprotective effects of different treatments, with media 
changed out and bright field pictures taken daily utilizing the Olympus IX71 microscope 
system. These were simple cell counts taken from 3 random fields of view per treatment 
(3 replicates) for 7 days.  Data were graphed as percent cell survival ((number of 
remaining cells/number of cells on start day)*100).  The minimum sample size was four 
for each treatment group. 
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A.3. Results  
 
We established a toxicity timeline in differentiated NG108-15 cells transfected with 
nAChRs and treated with full length Aβ (Fig. 7; ref 40). To examine the neuroprotective 
potential of Aβ1-15, we measured ROS and disintegrated nuclei in cultures co-treated 
with both Aβ1-42 and Aβ1-15 in different dosage and timing combinations. 
      For priming experiments, we showed that the Aβ1-15 pretreatment significantly 
blocked the action of Aβ1-42 via nAChRs as evidenced by the low ROS staining and 
reduced nuclear disintegration, either by competing for Aβ and/or activating cell survival 
pathways  (Fig. 11, p<0.001).  For the co-treatment experiments, the Aβ1-15 blocked Aβ1-
42 and any associated downstream effects also resulting in low ROS and nuclear 
disintegration (Fig. 11, p<0.001).  Surprisingly, neuroprotection in the delayed treatment 
(rescue) group was also significant (Fig. 11, p<0.01), though to a lesser degree than the 
co-treatment and priming groups. This rescue occurred despite the initiation of the 
cellular toxicity process by full-length Aβ1-42, namely increased ROS and nuclear 
disintegration indicating the start of apoptosis.  
The dose-response experiments produced unexpected results. Based on our 
electrophysiology studies that show very high potency of Aβ1-15 on synaptic plasticity 
(ref), we anticipated that Aβ1-15 would still have neuroprotective effects at very low nM 
levels.  At 10nM, Aβ1-15 was not able to significantly reduce ROS production with the 
100nM Aβ1-42 co-treatment (Fig. 11).  However, both the 100nM and 500nM Aβ1-15 co-
treatment were able to significantly prevent ROS production (Fig. 11).  Furthermore, our 
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antioxidant control, NAC reduced ROS similarly to Aβ1-15 and untreated control levels, 
confirming the staining was the result of ROS and not reactive nitrogen species. 
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Figure 11. The N-terminal Aβ 1-15 protects against Aβ-induced oxidative stress. Co-
treatment with Aβ1-15 at 10, 100 and 500nM. Priming: Treatment with Aβ1-15 1d prior to the 
start of co-treatment with Aβ1-42. Rescue: Co-treatment with Aβ1-15 1d subsequent to the start 
of treatment with Aβ1-42.  100 and 500nM as well as priming, rescue and co-treatment protect 
against Aβ toxicity. *p<0.05  ****p<0.0001 as compared to mock-transfected cells in one-way 
ANOVA with post-hoc test. Data are presented as 5-95 percentile box-and-whisker plots, n=4 
experiments/group from 3 random fields of view with 3 replicates per experiment.  
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 Nuclear disintegration data showed that combination treatments with Aβ1-15 or 
NAC are able to prevent nuclear disintegration caused by Aβ1-42 toxicity for all of the 
dosage and timing treatments (Fig. 12, p<0.0001).  Unlike the oxidative stress data, 
even the 10nM Aβ1-15 co-treatment with 100nM Aβ1-42 was enough to prevent nuclear 
disintegration caused by Aβ1-42. (Fig. 12), indicating that it may be sufficient to block 
apoptosis. 
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Figure 12. The N-terminal A β 1-15 protects against A β -induced nuclear 
disintegration: Conditions as described for Fig. 10. All co-treatment dosage and timing 
conditions protected against Aβ -induced nuclear disintegration.  Insets showing 
representative micrographs of cultures treated with Aβ1-15 or Aβ1-42 with arrow pointing to 
disintegrated nuclei. ****p<0.0001, .one-way ANOVA with post-hoc test. Data are 
presented as 5-95 percentile box-and-whisker plots, n=4/group.  
Aβ1-15	 Aβ1-42	
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Cell survival experiments demonstrate more accurately the timeline of cell death 
in differentiated NG108-15 cultures. Cells transfected with nAChRs and treated with 
Aβ1-42 die faster than non-transfected Aβ1-42-treated cells. Further co-treatment with 
either Aβ1-15 or Aβcore is neuroprotective against this toxicity (Fig. 13, p<0.0001 
compared to Aβ1-42). These changes were first detectable on day 5 when there was a 
significant decrease in cell survival in α4β2 nAChR-transfected cultures treated with 
Aβ1-42 (Fig. 13, p<0.05), followed by decreased survival of the mock-transfected cultures 
treated with Aβ1-42 on day 6 (Fig. 13, p<0.001).  This trend continued on to 7 days with 
both the transfected and mock-transfected NG108-15 cells treated with Aβ1-42, showing 
significantly higher cell death compared to combination treated cells with Aβ1-15 or 
AβCORE alone, or in combination with Aβ1-42 (Fig. 13, p<0.0001).	
Figure 13. The N-Aβ  fragment and the N-Aβcore protect against Aβ1-42 -induced cell death in 
NG108-15 cell culture.  A, Cell counts in NG108-15 cells with, or without, α4β2-nAChRs treated 
daily with 100nM Aβ1-42, N-Aβ fragment or N-Aβcore alone, or combination treatments with Aβ1-42 
and N-Aβ fragment or N-Aβcore over 7 days (n=4). (*p<0.05) (***p<0.001) (****p<0.0001). Data are 
means ± SEM, n=4 experiments/group from 3 random fields of view with 3 replicates per experiment.  
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B. Aim 1b EXAMINE THE NEUROPROTECTIVE EFFECTS OF THE N-
TERMINAL Aβ FRAGMENT IN EX-VIVO PRIMARY HIPPOCAMPAL CELL 
CULTURES. 
 
B.1. Experimental Design   
 
For primary hippocampal cell cultures, there are several steps we needed to resolve to 
prepare the cells for neuroprotection experiments. The experimental plan was as 
follows: 
1. First, it was necessary to establish neonatal mouse hippocampal cell cultures in 
which Aβ1-42 toxicity could be identified.  Approximately 6 days in culture under 
selection for neurons using Neurobasal media with B57 supplementation was 
sufficient for the majority of cells to assume polygonal somas and extend long 
Figure 14. Primary hippocampal  culture development over 6 days. 20x micrographs 
showing development of primary hippocampal neuron cultures taken from 1d old WT mouse 
over 6 days in culture. Arrow pointing to pyramidal neuron in culture. 
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neurites typical of cultured neurons.  Many of the neurons showed pyramidal 
neuron-like morphologies very similar to pyramidal cells in vivo. This is consistent 
with the continuation of hippocampal neuron development in vitro in parallel to in 
vivo development (Fig. 13).48 
2. Next, we established a timeline for Aβ1-42 toxicity in the neuronal cultures. This 
was achieved by treating the cultures with a high concentration of Aβ1-42 over 
several days to weeks.  ROS and cell counts were used to assess cell culture 
oxidative stress and viability at different treatment days to determine when the 
cells start deteriorating, and finally, cause most of the primary culture to diminish. 
Once the timeline was set, we were able to investigate the neuroprotective 
effects of Aβ1-15.   
3. Finally, we explored neuroprotective effects of Aβ1-15 on hippocampal cell 
cultures. This was accomplished by treating the cell cultures with different 
concentrations of Aβ1-15 in combination with full length Aβ. 	
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B.2. Materials and Methods: 
 
Animals:  
Neonatal B6.SJL mice (Jackson Labs) between 0-2 days old were used for primary 
hippocampal cell culture.  All animals used were in accordance with approved IACUC 
protocols and animal welfare guidelines.  
 
Primary Hippocampal Culture: 
Hippocampal cell cultures were prepared from 0-2 day old mice as described by Cheng, 
et al.58 Neonatal mice of either gender were swiftly decapitated, and the brains quickly 
extracted from the skull and placed in ice-cold Neurobasal A medium with 5% fetal 
bovine serum, Gentamicin and B27 supplement (serum NB). Hippocampi were then 
isolated using a dissecting microscope, minced and digested in a papain solution 
(Worthington, LS003126, Lot # 35N16202) for 15 minutes in a 37°C incubator. The cells 
were then centrifuged and washed twice with serum NB, and then serially triturated with 
three polished Pasteur pipettes of decreasing diameter to dissociate the cells. The 
primary cells were then centrifuged one last time, washed with serum NB and plated on 
24-well plates coated with poly-D-lysine (after 15 minute pre-plating to remove adherent 
glial cells).  Cells were maintained in Neurobasal A medium with B27 and Gentamicin 
and treatment begun after 1 week in culture, spanning 5 or 10 days with ROS and cell 
survival experiments as described in Aim 1a. 
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Treatments: 
The Aβ toxicity timeline was established by treating primary cultures with micromolar Aβ 
concentrations over several days. ROS Image iT Live assay kit was utilized and 
visualized as described in Aim 1.  
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B.3. Results 
 
We were able to successfully culture primary hippocampal cells and establish an Aβ1-42 
toxicity timeline in these cultures. Early experiments indicated the need to treat the cell 
cultures with higher (µM) doses of Aβ1-42, compared to the lower nM doses used in 
differentiated NG108-15 cells expressing nAChRs, in order to induce measurable 
toxicity.  
 After five days of treatment there was already a significant difference in ROS 
between Aβ1-42 treatments compared to all other treatments (Fig. 15, p<0.0001).  Both 
the Aβ1-15 and Aβcore combination treatments with Aβ1-42  were able to protect the primary 
Figure 15. The N-Aβcore and the N-Aβ  fragment protect against Aβ1-42-induced 
oxidative stress in primary hippocampal neurons.  5-day treatments with 1µM Aβ1-
42, 1µM and 100nM N-Aβ fragment, or 1µM and 100nM N-Aβcore and combination 
treatments of 1µM Aβ1-42 and 1µM or 100nM N-Aβ fragment or 1µM or 100nM N-Aβ
core (n=4). Percent positive ROS cells represented by 5-95 percentile box-and-whiskers 
plots (n=4 experiments/group from 3 random fields of view with 2 replicates per 
experiment.  
) ***p<0.0001 (Tukey post hoc tests) 
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cells from this toxicity, with ROS levels comparable to untreated control levels (Fig. 15, 
p<0.0001, compared to Aβ1-42).  Interestingly, in the primary hippocampal cells, the 
100nM Aβ1-15 or Aβcore treatments in combination with 1uM of Aβ1-42 were still able to 
significantly prevent ROS production due to Aβ1-42 toxicity (Fig. 15, p<0.0001) 
Ten-day treatments produced results similar to the 5-day treatments with 
differences becoming even more pronounced between the different treatment groups.  
Aβ1-42-treated groups exhibited higher levels of ROS (compared to 5-day treatment) and 
with combination-treated groups produced lower levels, in some cases comparable to 
untreated control levels (Fig. 16, p<0.0001 untreated and combination-treated groups 
compared to Aβ1-42).  
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Figure 16. The N-Aβcore and the N-Aβ  fragment protect against Aβ1-42-induced oxidative 
stress in primary hippocampal neurons. 10-day daily treatments with 1µM Aβ1-42, 1µM N-Aβ 
fragment, or 1µM N-Aβcore and combination treatments of 1µM Aβ1-42 and 1µM N-Aβ fragment 
or 1µM N-Aβcore (n=4). Percent positive ROS cells represented by 5-95 percentile box-and-
whiskers plots (n=4 experiments/group from 3 random fields of view with 2 replicates per 
experiment.  ***p<0.0001 (Tukey post hoc tests) 
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We also explored glutamate toxicity to examine whether Aβ1-15 or Aβ10-15 are able to 
protect against excitotoxicity and saw similar levels of ROS production as Aβ1-42 at five 
days of glutamate treatment at 100µM.  Glutamate (100µM) treated cultures caused 
significantly high oxidative stress compared to untreated controls (Fig. 17, p<0.0001) 
with significant reduction by combination treatment with Aβ1-15 at 1µM (Fig 17, p<0.001).  
All other combination treatments showed no significant reduction of ROS. 
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Figure 17. The N-Aβcore and the N-Aβ fragment are unable to protect against 
glutamate-induced oxidative stress in primary hippocampal neurons.  5-day 
treatments with 100µM Glutamate, 1µM and 100nM N-Aβ fragment, or 1µM and 100nM N-
Aβcore and combination treatments of 100µM Glutamate and 1µM or 100nM N-Aβ 
fragment or 1µM or 100nM N-Aβcore (n=4). Percent positive ROS cells represented by 5-
95 percentile box-and-whiskers plots (n=4 experiments/group from 3 random fields of view 
with 2 replicates per experiment. ***p<0.0001 (Tukey post hoc tests) 
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Cell survival experiments taken out to 10 days give us a better understanding of 
the neuroprotective effect of these treatments on the primary neurons. There was a 
much faster rate of cell death in Aβ1-42 treated cells compared to the other groups.  Both 
Aβ1-15 and Aβcore were protective against this Aβ1-42 toxicity. At day 5 we detected a 
significant decline in cell numbers when treated with Aβ1-42 (Fig. 18, p<0.0001), which 
continued to decline until day 10.  This cytotoxicity was prevented by co-treatment with 
either Aβ1-15 or the core fragment Aβ10-15 (Fig. 18, p<0.0001). 	
Figure 18. The N-Aβ  fragment and the N-Aβcore protect against Aβ 1-42 -induced cell 
death in primary hippocampal neurons. Cell counts in primary hippocampal cell cultures 
treated daily with 1µM Aβ1-42, N-Aβ fragment or N-Aβcore alone, or combination daily 
treatments with A β 1-42 and N-A β  fragment or N-A β core for 10 days (n=4 
experiments/group from 3 random fields of view with 2 replicates per experiment).  
Averaged data are means ± SEM, *p<0.05, **p<0.001, ***p<0.0001 (Tukey post hoc tests). 
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Discussion  
 
Due to its short, hydrophilic nature, as well as its strong agonist-like action via nAChRs, 
Aβ1-15 is an endogenous peptide that was speculated to have neuroprotective function.2 
The current work shows that Aβ1-15 is not only non-toxic, but is also neuroprotective in 
both nAChR-transfected NG108-15 cells as well as primary hippocampal neuronal 
cultures.  
From ROS experiments in NG108-15 cells, nAChRs sensitized cells to Aβ1-42 as 
previously reported.39 Part of the pathophysiology of AD causing high Aβ deposition is 
the impairment of the cholinergic nAChR system.34 Furthermore, in AD brains, the 
neurons expressing nAChRs are the most vulnerable against Aβ toxicity.35 Aβ toxicity 
could partly be mediated by nAChRs, as it triggers signaling cascades such as the MAP 
kinase-linked signaling pathways, specifically activating ERK and JNK followed by 
increased PHF-tau leading to increased ROS production and cell death.57 Our lab has 
shown these signaling cascades to be activated in NG108-15 cells transfected with 
α4β2 nAChRs, wherein Aβ toxicity presents within the first day of treatment. 
Alternatively, there are nAChR-linked neuroprotection pathways.  The PI3/AKT pathway 
is an anti-apoptotic pathway that is well understood in nicotine neuroprotection.35 This 
could possibly be the alternative neuroprotective pathway being activated by Aβ1-15.  It is 
interesting to see that priming and the Aβ1-15 co-treatment (100nM and 500nM) could 
prevent Aβ-induced ROS production, suggesting that a neuroprotective pathway 
activated before or within the same timing as full-length Aβ is sufficient enough to 
prevent activation of ROS-producing or cell-death pathways. Curiously, the dose-
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response relationship for Aβ1-15 protection against Aβ1-42 –induced ROS differed from 
that seen for nuclear fragmentation. Moreover, the dose-response relationship was 
quite steep, indicating an unconventional interaction between Aβ1-15 and Aβ1-42 , either at 
the level of the target receptor(s) and/or downstream signaling.    
In contrast, introducing Aβ1-15 one day after Aβ42 treatment did reduce ROS 
significantly, but not to baseline levels.  This suggests that the Aβ-toxicity pathway had 
already commenced, and the attenuation by Aβ1-15 may have been predominantly 
mediated by interrupting the toxicity signaling pathways and/or activating anti-apoptotic 
pathways. These may be primary pathways initiated in the α4β2 nAChR-transfected 
NG108-15 cell line, and future experiments could be directed toward examining them. 
It would not be surprising, however, that there are several other pathways 
involved in the more physiologically relevant primary hippocampal neuron cultures. In 
fact, a recent study exploring insulin-mediated protection against Aβ toxicity in primary 
cultures showed decreased phosphorylation of Akt, and this is prevented by insulin.  In 
contrast, Aβ increased ERK phosphorylation in parallel with apoptosis which was also 
prevented with inhibition of ERK phosphorylation by insulin.59 These could be possible 
pathways targeted by Aβ1-15.  
In addition, our test of the Aβ1-15 and Aβcore against glutamate excitotoxicity 
showed that only the Aβ1-15 at micromolar concentrations was able to partially decrease 
ROS. These data suggest that the neuroprotection by the N-terminal fragment and the 
N-terminal core fragment is more selective for Aβ toxicity. 
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This study clearly shows that Aβ1-15 is able to prevent oxidative stress production 
and nuclear disintegration due to Aβ1-42 toxicity in both the model neuroblastoma cell 
line as well as the more physiologically relevant primary hippocampal cells.  This effect 
is shown in early stages of toxicity (5-day treatments in primary cells) as well as later 
stages of toxicity (10-day treatments in primary cells), providing us with ample data 
supporting our hypothesis that Aβ1-15 is neuroprotective against Aβ42 toxicity in our in 
vitro and ex-vivo model systems. 
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CHAPTER 3 
THE NEUROPROTECTIVE ACTION OF Aβ1-15 AGAINST Aβ1-42-
TRIGGERED DEFICITS IN SYNAPTIC PLASTICITY 
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THE NEUROPROTECTIVE ACTION OF Aβ1-15 AGAINST Aβ1-42-TRIGGERED 
DEFICITS IN SYNAPTIC PLASTICITY. 
 
Introduction 
 
Cognitive impairments, especially compromise of short-term memory, are among the 
first symptoms that present in AD patients.  This is due to the synaptic dysfunction 
triggered by Aβ oligomers involved in the pathogenesis of AD.25,60 This, in turn, causes 
impairments in long-term potentiation (LTP), an essential link to memory processing in 
the hippocampus.  Specifically, long-term potentiation is a mechanism by which 
synaptic strengthening occurs.  LTP can be sustained for several hours in vitro and 
several months in vivo, demonstrating a physiological change important for learning and 
memory.61   
The work produced by Puzzo et al. showed that Aβ is a neuromodulator that has 
hormetic effects: At low picomolar levels it enhances LTP, but at high nanomolar 
concentrations it inhibits LTP.7,9,27 In AD, Aβ is produced in high amounts, leading to 
deficits in synaptic plasticity and memory.  Aβ is also known to regulate several major 
intracellular pathways that are downstream from NMDA receptor signaling.  Key 
components of these pathways include: calcineurin, CAMKII, cAMP/PKA, protein 
phosphatase I, and CREB.62,63 There is growing evidence that suggests a strong 
association of LTP deficits and Alzheimer’s disease, implying LTP impairment could be 
an early event in AD pathology.64 
To better understand the possible neuroprotective effects of Aβ1-15, we used this 
information to first, examine whether Aβ1-15 had similar hormetic effects on LTP; then, to 
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test if Aβ1-15 can prevent LTP inhibition by Aβ42; and finally, to examine whether Aβ1-15 
could potentially rescue LTP in an AD mouse model known to have synaptic 
dysfunction.	
1. Experimental Design:  
 
Three electrophysiology experiments were performed to examine a variety of effects of 
Aβ1-15, on synaptic plasticity. These are:  
1. Aβ1-15 dosage effect on synaptic plasticity-  
According to our previous findings with confocal calcium imaging, Aβ1-15 is highly 
potent and active via nAChRs.2 Dosage effects of AS1-15 on synaptic plasticity are 
therefore important to consider.  WT hippocampal brain slices were perfused with 
either aCSF alone, or 50nM, 50pM or 50fM Aβ1-15, for 20 minutes before theta-
burst stimulation (TBS) and field potentials (fEPSPs) were recorded for an hour 
to observe dosage effects on LTP. 
2. Inhibition of LTP by Aβ1-42 and potential reversal by Aβ1-15 –  
Hormetic effects of Aβ1-42 have been clearly shown by Puzzo et al., with high nM 
levels blocking LTP.  If Aβ1-15 is neuroprotective, it should be able to reverse this 
block.  To demonstrate this, we first perfused WT slices with 500nM Aβ1-42, to 
confirm blocking of normal high-frequency stimulation (HFS) LTP by full-length 
Aβ.  After this was confirmed, we proceeded with a priming experiment in which 
slices were perfused with Aβ1-15 for 20 minutes, followed by perfusion of Aβ1-42 for 
another 20 minutes, followed by HFS.  Responses were recorded for an hour to 
investigate the long-term effect of the priming of synapses with Aβ1-15.  
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3. LTP rescue by Aβ1-15 in APPswe mice-  
APPswe mice carry a transgene for APP with the Swedish mutation (APP695 with 
double mutation K670N and M671L, Taconic). They have been shown to exhibit 
LTP deficits beginning at 3-5months of age.65,66 We hypothesized that Aβ1-15 may 
be able to rescue or reverse LTP deficits in this mouse model of AD.  To test this 
hypothesis, LTP deficits had to be first confirmed in APPswe mice, and this was 
achieved by perfusing aCSF alone onto the brain slice for 20 minutes, followed 
by the basic HFS protocol and recording for 1 hour to observe long-term effects.  
Next, to examine the effect of Aβ1-15 on APPswe LTP deficit, the APPswe 
hippocampal slices were perfused with Aβ1-15 for 20 minutes before HFS and 
responses were recorded for an hour to observe the long-term effects of the Aβ1-
15 on synaptic plasticity.  Controls involved the same treatments on brain slices 
from wild-type littermates. 	
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2. Materials and Methods  
 
Animals: 
Electrophysiology was performed on hippocampal slice cultures prepared from 2- to 5-
month-old C57BL/6J mice (Jackson Laboratory) or 5- to 6-month-old APPswe and 
B6.SJL (background control) mice (Taconic Biosciences). All animal studies were 
carried out following approved IACUC protocols in accordance with animal welfare 
guidelines. 
 
Acute Slice preparation: 
Swift cervical dislocation and decapitation was performed on the mice (as per an 
approved IACUC protocol). The brains were extracted and transversely sliced at 350µm 
using a Leica vibrating microtome (Leica, VT1200S) in artificial cerebrospinal fluid 
(aCSF) consisting of: 130mM NaCl, 3.5 mM KCl, 10mM glucose, 1.25mM NaH2PO4, 
2.0mM CaCl2, 1.5mM MgSO4, and 24mM NaHCO3, equilibrated at pH 7.4.  The 
hippocampi were then dissected out using a dissecting microscope, the slices were 
incubated for 30mins in 95% O2/5% CO2 in aCSF at room temperature, then transferred 
into a 32°C water bath for another 30-min incubation before electrophysiological 
recording.2 
 
Electrophysiology: 
Slices were stimulated at the Schaffer collaterals at 0.1Hz with 3V using a bipolar 
stimulating electrode and recorded from the CA1 pyramidal cells with a glass electrode 
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filled with 3M NaCl.  Stimulation was set to 20-40% of maximum response via two 
different stimulation protocols. LTP data are presented as averaged field EPSP slope 
per minute. 
1.  Theta-burst stimulation (trains of four pulses at 100 Hz, with 10 trains 
delivered at 5 Hz, each repeated three times every 15 s (three bursts)) or  
2. High frequency stimulation (two single trains of 100 Hz separated by 20 s) 
after perfusion of different concentrations of either Aβ1-42, or Aβ1-15 was applied 
as described in Lawrence, Tong, et al, 2014.2 	
 
Statistics: 
ANOVA with Bonferroni post hoc test was used to compare conditions (last 10 minutes 
for LTP).  At least 4 biological replicates were performed for each study. The minimum 
criteria for significance was p<0.05.  All data were plotted ± SD. 
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3. Results:   
 
We initially tested whether the potential impact of Aβ1-15 on LTP would be dependent on 
the timing of perfusion (before or after HFS). Preliminary tests on WT hippocampal 
slices showed the treatment media had to be perfused before HFS to see the LTP 
effect, as no effected was seen with treatment perfused after HFS (Fig. 19A). It was 
important to establish a stable baseline that does not drift to make conclusions about 
sustained LTP, so we tested the effect of Aβ1-15 on baseline synaptic activity. The 
perfusion of different concentrations of Aβ1-15 (100pM and 100nM) did not significantly 
alter baseline synaptic strength (Fig. 19B). 
Wild-type hippocampal slices were subsequently perfused with different 
concentrations of Aβ1-15 and basic LTP experiments were performed using theta-burst 
stimulation. We initially tested for significant differences in baseline synaptic strength 
that could perhaps affect our results.  We assessed this by measuring fESPS versus 
stimulus intensity, and plotting input/output curves with increasing stimulation, showing 
no differences between slices (Fig 20A). We compared theta-burst potentiation and saw 
a significant difference in early potentiation in slices perfused with femptomolar but not 
picomolar concentrations of Aβ1-15  (Fig. 20B, p<0.05). Surprisingly, the Aβ1-15 fragment 
was able to sustain enhanced LTP at a concentration of 50fM (Fig. 20C & D, p<0.05), 
an unexpectedly high potency.   
We then directly examined the effect of Aβ1-15 on Aβ1-42-treated slices. High-
frequency stimulation LTP was substantially attenuated by 100nM Aβ1-42 perfused into 
the slice for 20 minutes before stimulation (Fig. 20E & F, p<0.05), as previously 
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reported.7 Pre-incubation of the brain slice with Aβ1-15 for 20 minutes before full length 
Aβ perfusion was able to prevent this LTP block by Aβ1-42, restoring LTP to control levels  
(Fig. 20E & F, p<0.05).  
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Figure 19. The N-terminal Aβ1-15 has no significant effect on baseline synaptic activity 
and has to be perfused before HFS to have an effect on LTP. Effect of Aβ1-15 perfusion in 
WT brain slices: A. on baseline synaptic activity showing no significant baseline drift with Aβ1-15 
perfusion at 100pM or 100nM concentrations. 5mM calcium used as a positive control B. before 
or after HFS showing perfusion of treatment media before HFS is required for LTP 
enhancement. on baseline synaptic activity showing no significant baseline drift with Aβ1-15 
perfusion at 100pM or 100nM concentrations. 5mM calcium used as a positive control. Data 
plotted are means ± SD (*p<0.05) 	
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Figure 20. Aβ1-15 enhances LTP at femptomolar concentrations and can prevent LTP block 
by Aβ1-42. A-D. LTP experiments with TBS in presence or absence of Aβ1-15 in WT slices. A. 
Control input/output curves, before treatment.  B & C. 50fM Aβ1-15 can significantly increase PTP 
and LTP. Color coded insets showing control fEPSPs for control aCSF (black), 50pM Aβ1-15 
(green), and 50fM Aβ1-15 (red) D. Averaged fEPSP values for final 10 minutes of LTP showing 
significantly enhanced LTP in WT slices treated with Aβ1-15. 
E & F. LTP experiments with HFS in absence or presence of Aβ1-42 with or without pretreatment 
with Aβ1-15 in WT slices showing rescued LTP when pre-treated with 500nM Aβ1-15 compared to 
LTP blocked by Aβ1-42 alone. Color coded insets showing fEPSPs for control aCSF (black), 500nM 
Aβ1-15 (green), and 500nM Aβ1-42 (blue) F. Averaged fEPSPs for last 10 minutes of LTP as noted 
by solid black bar in E representing LTP rescue by Aβ1-15. n= 6 slices/ group. Data plotted are the 
means  ± SD *p<0.05 (Bonferroni post hoc tests). 
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Lastly, APPswe mouse acute hippocampal slices were used in HFS LTP experiments. 
First, when the WT slices were perfused with Aβ1-15 before HFS, we saw no differences 
between slices compared to aCSF alone. In contrast, APPswe mice are known to have 
HFS LTP deficits, and this was confirmed by perfusing aCSF alone and performing 
basic LTP (Fig. 21A & B, p<0.05). APPswe slices that were perfused with Aβ1-15 before 
HFS, showed this deficit was eliminated (Fig. 21A & B, p<0.05).  These data support our 
hypotheses that Aβ1-15 can both rescue LTP and protect against the effects of Aβ1-42, 
here produced endogenously in the transgenic APPswe. 
 
Figure 21. Aβ1-15 restores normal LTP in APPswe mouse hippocampal slice. A. HFS-
induced LTP with color-coded insets showing example fEPSPs for slices from WT mice 
with or without pretreatments with 500nM Aβ1-15 (red) or slices from APPswe mice with or 
without pretreatment with 500nM Aβ1-15. Period of Aβ1-15 pre-treatment marked with an 
open bar. B. Average fEPSP slope values for the last 10 minutes of LTP as noted by the 
solid bar in A. n= 4slices/group. Data plotted are the means  ± SD *p<0.05 (Bonferroni 
post hoc tests). 
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Discussion: 
 
It is well established in the literature that Aβ oligomers disrupt synaptic signaling via 
interaction with various receptors perturbing various signaling pathways (Fig. 22) 
(reviewed in ref 1). While the molecular mechanism is not well understood, it is 
generally believed that high concentrations of Aβ oligomers trigger overstimulation via 
multiple pathways, causing abnormal redox reactions and calcium upregulation. This is 
followed by the activation of downstream pathways that cause a cascade of pathological 
events including the production of high oxidative stress, mitochondrial dysfunction, 
synaptic dysfunction and neuronal loss.39,64,67,68 
 
 
Figure 22. Proposed molecular mechanisms of Aβ  synaptotoxicity.1  
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In this study we observed that, comparable to full-length Aβ, Aβ1-15 was able to 
enhance LTP at low concentrations when it was perfused before TBS, further confirming 
its neuromodulatory function.  It would be interesting to examine possible hormetic 
effects as reported by Puzzo et al. (2010), wherein full length Aβ was shown to enhance 
LTP at low pM concentrations but block LTP at higher nanomolar concentrations.7 This 
would be rather unlikely due to the short, hydrophilic nature of Aβ1-15 and the fact that at 
picomolar levels it had no effect on TBS LTP (Fig.20, A-D).  
It is surprising to see that in our experiments, Aβ1-15 was completely able to 
reverse LTP deficits induced by Aβ1-42. The mechanism by which this was achieved is 
currently unknown due to the large number of intracellular pathways with which Aβ42 
oligomers can interact. However, we can conjecture from the known LTP mechanism 
that there could be a rapid upregulation of AMPA receptor trafficking to the 
synapse.38,40,62 It could also simply be that Aβ1-15 is blocking the binding of Aβ42 to its 
target receptors, thus blocking its deleterious effects and allowing recovery to the 
‘normal’ state.  The latter is unlikely to be the only mechanism acting, due to the ability 
of Aβ1-15 to rescue memory in APPswe mice in which elevated levels of toxic Aβ are 
already present for weeks to months. 
Similar studies exploring synaptic plasticity showed that pre-treatment of slices 
with Neurotrophin 4 rescued LTP impairment caused by Aβ-induced deficits that 
resulted in impaired CAMKII signaling pathways.69 This study was focused on CAMKII 
downstream from the NMDA receptor and the phosphorylation of AMPA receptors 
dependent on CAMKII. BDNF and Neurotrophin 4 were both able to enhance CAMKII 
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and AMPAR phosphorylation and compete against Aβ inhibition to enhance LTP in co-
treated slices.69 While this was an exciting study, it focused solely on CAMKII and 
AMPA receptors.  However, it would be interesting to investigate the impact of Aβ1-15 on 
neurotrophins. 
A similar study explored the effect of resveratrol on Aβ toxicity.  The authors were 
able to show that resveratrol prevented LTP impairment in vivo in correlation with 
rescued CREB activation that was also inhibited by Aβ.70 Resveratrol is able to rescue 
CREB activation, which is able to bind BDNF promoters, which, in turn, increases 
AMPA receptor activity.71  
It would be interesting assess whether Aβ1-15 has similar effects on these specific 
receptors and downstream signaling pathways (explored in Chapter 4), but also 
important to understand how Aβ1-15 is interacting with other pathways, or if it is just 
blocking the effects of Aβ1-42.  
While this study shows significant effects of the Aβ1-15 fragment on LTP, more in-
depth electrophysiology studies exploring effects of Aβ1-15 on long-term depression 
(LTD), which we know is enhanced by Aβ42, and sub-threshold LTP, need to be 
performed and the mechanisms involved should be further explored.  
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CHAPTER 4 
THE NEUROPROTECTIVE ACTION OF Aβ1-15 AGAINST Aβ1-42-
TRIGGERED CHANGES IN FEAR MEMORY AND ANXIETY. 
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THE NEUROPROTECTIVE ACTION OF Aβ1-15 AGAINST Aβ1-42-TRIGGERED 
CHANGES IN FEAR MEMORY AND ANXIETY. 
 
Introduction: 
 
Cognitive decline, including memory loss, is considered an early symptom in AD, but 
they occur fairly late in the pathophysiology of the disease, often fifteen to twenty years 
after amyloid accumulation first occurs (Fig. 23).1 In later stages, AD patients display 
increased anxiety and agitation.  
        The current FDA-approved treatments for AD fall under two categories: 
Cholinesterase inhibitors and NMDA receptor antagonists. Both are able to lessen 
Figure 23. Timeline of the pathophysiology of AD1 Amyloid deposition begins 15-20 years 
before any cognitive symptoms arise. 
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severity of symptoms for a limited amount of time but not cure the disease.24,72 This 
makes it imperative to explore new avenues for AD therapies. 
Amyloid-β oligomers are responsible for perturbing various functions within and 
between neurons.  They disrupt mitochondrial function, cholinergic signaling, and 
overall calcium homeostasis, while also activating stress pathways.35,56,73 As previously 
noted, in relation to learning and memory, we know Aβ binds synapses in the 
hippocampus, specifically excitatory synapses that express NMDA receptor subtypes 
NR1 and NR2B.68 There is also evidence showing that Aβ interacts with several other 
receptors affecting intracellular pathways downstream of receptor signaling (see Fig. 
22), which in turn, translate to memory deficits.62  
 To best understand the phenotypic 
alterations caused by Aβ toxicity and the possibility 
of preventing those alterations using the N-terminal 
Aβ1-15 fragment , we explored several behavior 
paradigms in a well-established AD mouse model, 
5XFAD, to examine learning deficits affected by Aβ 
accumulation in different parts of the brain.  The 
earliest and most severe alterations occur in the 
hippocampus and entorhinal cortex of the medial 
temporal lobe.55 These areas will be the focus of 
these tests. The three behavior tests we used to 
focus on these regions were: (1) Contextual fear conditioning (CFC), exploring 
Figure 24. At 100pM, A β 1-15 
enhances memory in WT mice. 
Bilateral injection of 100pM, 100nM 
Aβ1-15, or saline into the dorsal 
hippocampus 24 hours before single 
trial CFC testing.  Freezing was 
measured via TSE videotracking 
software.  Data are means ± SEM 
*p<0.05 3 
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contextual and fear memory; (2) Novel object recognition (NOR), examining recognition 
memory; and finally, (3) the Elevated plus maze (EPM), to observe the effect of the N-
terminal Aβ fragment on anxiety levels.  The rationale for exploring the potential for N-
terminal Aβ fragment protection against Aβ-linked behavioral deficits in the AD mouse 
model was based in the demonstration that Aβ1-15 enhanced CFC in wild-type mice (Fig. 
24), further supporting the neuromodulatory role for the N-terminal Aβ fragment. 
In coordination with memory tests we also tested for changes (compared to WT 
saline injected mice) in the NMDA (N-methyl-D-aspartate)-type and AMPA (α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid)-type glutamate receptor subunits, which 
are linked to memory processing. We also tested for changes in activated JNK (c-Jun 
N-terminal kinase) and ERK (extracellular signal-regulated kinase), which are linked 
both to memory and neurotoxicity. Finally, we investigated CREB (cAMP response 
element binding protein) signaling, which plays a central role in memory.  The overall 
goal for this study was to investigate whether Aβ1-15 improves the AD phenotype in vivo 
and elucidate the signaling mechanisms involved. 
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1. Experimental Design:  
 
Learning and memory deficits are the first symptoms to appear in AD, and these deficits 
progress rapidly, disrupting patients’ lives.  These consequences underscore the 
importance of studying the effects of Aβ on memory, and exploring ways to enhance 
memory or reduce memory deficits in AD.  To parallel the electrophysiology studies and 
investigate memory deficit reversal in an AD mouse model, we performed various 
behavioral assays. 
 
5XFAD mouse model: 
The 5XFAD mouse model (MMRC Stock # 34840-JAX, Tg 6799: B6SJL-
Tg(APPSwFlLOn,PSEN1*M146L*L286V) was found to be best suited for the behavioral 
experiments due to its accelerated AD pathology leading to early plaque deposition, 
neuron loss and memory deficits.74 This AD mouse model is a transgenic multiple 
APP/Presinilin 1 (PS1) model expressing five FAD mutations leading to high Aβ 
production and deposition. Like many AD mouse models, it lacks neurofibrillary tangle 
formation.  Regardless, the age-dependent neurological deficits it displays resemble key 
common phenotypes in AD patients, particularly with regard to Aβ-linked pathology, 
making it an ideal model for use in behavior testing.  
   
Contextual Fear Conditioning (CFC): 
Fear conditioning tasks are well-established tests that examine associative memory 
affected in AD patients.  The brain regions involved in FC are the amygdala and the 
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hippocampus.  The hippocampus is involved in the learning of the context that triggers 
fear. The amygdala, on other hand, is a brain structure highly involved in the fear circuit.  
Therefore, the hippocampus acts as a sensory relay communicating the context to the 
amygdala about the environment of the dangerous event. 
1. First, we aimed to confirm that the 5XFAD mice did indeed display memory 
deficits compared to their wild-type counterparts in our experimental system. 
Behavior experiments (such contextual/cued fear conditioning, elevated plus 
maze, and novel object recognition) were performed on 5XFAD and WT mice at 
6-7 months of age (when memory deficits begin to appear)75–77. Once the 
conditions were established that revealed memory deficits in 5XFAD mice 
compared to WT mice, we were able to move on to rescue experiments. 
2. Memory rescue: 5XFAD mice have been shown to have memory deficits in CFC, 
making them an ideal AD model to test Aβ1-15-induced memory rescue.78, 79 
Based on our dosage effects from previous experiments8, we used the most 
effective Aβ1-15 concentration (500nM or control saline) to inject into the dorsal 
hippocampus of 5XFAD mice and then train and test in CFC and other behavior 
paradigms to see whether Aβ1-15 can rescue memory deficits in the 5XFAD mice.  
It would be very significant to be able to show a memory rescue in vivo in an 
established AD mouse model and would further support our hypothesis of Aβ1-15 
being neuroprotective. 
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Novel Object Recognition (NOR): 
Impairment of recognition memory is part of declarative memory deficits that present in 
AD patients. Novel object recognition tests evaluate recognition memory using a simple 
task with no outside reinforcement, thereby testing a rodent’s natural preference for 
novel objects. The brain regions involved in NOR are the hippocampus and the 
perirhinal cortex. The perirhinal cortex is necessary for representation of basic 
information of whether an object is familiar or novel.  The hippocampus is important for 
encoding data linked to that basic information connected to the experience within the 
object-related context.80   
 
Elevated Plus Maze (EPM): 
The elevated plus maze (EPM) is a well-known test of unconditioned anxiety.  It takes 
advantage of the rodent’s natural preference for a protected, dark area.81 The brain 
regions involved in EPM are the amygdala, hippocampus, and cingulate and prefrontal 
cortices.81,82  
 
Protein Extraction and Western Blot:  
To begin to elucidate the mechanisms by which the N-terminal peptide can cause 
behavioral changes in the 5XFAD mouse model, we extracted hippocampal proteins 
and preliminarily assessed molecular level changes involved in learning and memory as 
well as stress pathways known to be activated by the toxic full length Aβ.    
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2. Materials and Methods 
 
Animals:  
For each of the behavior experiments, 6.5-8-month old 5XFAD mice or age-matched 
wild-type B6.SJL mice of roughly equal numbers of either sex were used (Jackson 
Laboratories). All animal use was followed with approved IACUC protocols in 
accordance with animal welfare guidelines. 
 
Stereotaxic Cannulation Surgery: 
In collaboration with Drs. Cedomir Todorovic and Tessi Sherrin, contextual fear 
conditioning was utilized to test learning and memory in WT and 5XFAD mice after 
bilateral microinjection over 30s with saline, 500nM Aβ1-15, or 500nM Aβ10-15 in a 
maximum volume of 0.40µL injected into each side.  Stereotaxic cannulae implantation 
was implemented as described (Sherrin et al., 2010).  5XFAD or age-matched B6.SJL 
mice were fully anesthetized with 1.2% Avertin and cannulae inserted using the 
following stereotaxic coordinates relative to Bregma: -1.5mm anteroposterior, ±1mm 
lateral, and -2mm depth into the dorsal hippocampus. 
After 7 days of recovery the dorsal hippocampi were 
bilaterally injected with either Aβ1-15, Aβ10-15, or saline 
before single-trial CFC, or NOR were performed.  
Cannula placement was checked in randomly 
assigned mice after behavior experiments by 
dissection and transverse slicing of the brain to look 
Figure 25. Cannula placement 
confirmation. Cannula placement 
confirmed by transverse slicing of 
brain to identify cannula tracks into 
the dorsal hippocampi (arrows). 
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at cannula tracks (Fig. 25).  
 
Contextual Fear Conditioning: 
Single-trial Contextual Fear Conditioning (CFC) consists of a 180 second exposure to a 
context that consisted of a fear conditioning box containing a plexiglass cage (36 x 21x 
20cm) where the mouse explores the context, followed by a mild foot shock of 0.8mA 
for 2 seconds delivered through a stainless-steel grid floor.  Contextual fear memory 
recall was tested after 24 hours by measuring freezing response (absence of 
movement) when the mouse was placed back in the conditioning context.  In an 
subsequent experiment testing remote memory, a test was performed wherein the 
conditioned mouse was re-introduced to the context 12 days after initial training.  Basic 
locomotion and shock were automatically measured and set by using TSE systems 
computer-controlled fear conditioning software (TSE, Bad Homburg, Germany).  
Freezing, which is defined as a lack of movement, was recorded every 10 s for a total of 
18 sampling intervals (180 s total) by an observer that was blinded to treatments. A 
minimum sample size of 6 per group were used for all Aβ1-15 experiments, or 3-4 per 
group for preliminary Aβ10-15 experiments. Data were graphed and analyzed using one-
way ANOVA on Prism (GraphPad).  
 
Novel Object Recognition: 
NOR consisted of 3 phases over three days: Habituation phase, Familiarization phase, 
and Testing phase.  The Habituation phase was simply a 10-min open field phase in 
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which the mice were able to explore the open field box where the NOR test would later 
be performed.  Total distance traveled and time spent in the center of the open field 
were recorded to ensure similar activity between all groups as well as looking at 
differences in thigmotaxis between groups. The Familiarization phase was performed 24 
hours after the Habituation phase and it consisted of the reintroduction of the mice into 
the open field, but this time with 2 identical objects placed in opposite corners of the 
open field box approximately 40cm from the outer walls.  In this phase, the time spent 
with each object as well as the number of visits to each object was recorded.  The third 
and final phase was the Testing phase in which one of the 2 identical objects was 
replaced with a novel object that was different in shape and color but roughly similar in 
size.  For the final phase the total time spent with each object and total visits per object 
were recorded.  All animal behavior was recorded by a camera connected to a PC and 
analyzed by video tracking software (VideoMot 2, TSE Systems). For all phases, total 
distance traveled was recorded to confirm similar activity between all groups.  The 
percentage of time spent exploring novel vs. familiar objects and a discrimination index 
were plotted. A minimum sample size of 7 per group were used for 5XFAD groups, or 2-
3 per group for WT. Data were graphed and analyzed using one-way ANOVA on Prism 
(GraphPad). 
 
Elevated Plus Maze: 
The elevated plus maze is made of four arms that radiate from a central platform with 
two opposing closed arms with tall dark walls and two opposing open arms forming a 
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plus shape, elevated 1 meter from the floor.  Mice were placed in the central platform 
facing an open arm and allowed to explore for 5 minutes.  All animal behavior was 
recorded by a camera connected to a PC and analyzed by video tracking software 
(VideoMot 2, TSE Systems). Recorded data include: Total distance traveled, time spent 
in open/closed arms, and visits per closed/open arm.  Percent of time spent in open 
arms as well as discrimination ratios were plotted.  A minimum sample size of 7 per 
group were used for 5XFAD groups, or 2-3 per group for WT. Data were graphed and 
analyzed using one-way ANOVA on Prism (GraphPad). 
 
Protein Extraction: 
Hippocampi were rapidly dissected from brains removed from animals 24hrs after Aβ 
injection and then flash-frozen in liquid nitrogen.  Proteins from full hippocampi were 
extracted by homogenizing the tissue in Pierce lysis buffer (Thermo Scientific, 
cat#87788) with protease/phosphatase inhibitors, then gently rotated at 4°C for 20 
minutes followed by centrifugation at 18,000g at 4°C for 20 minutes.  The supernatant 
was saved and protein concentration was measured using a BCA kit. Supernatant from 
this lysis / homogenization extraction was equivalent to the cell cytosol. 
 Extracting compartment proteins was achieved using a compartmental protein 
extraction kit (Millipore, cat#2145).  Briefly, each compartment extraction was achieved 
by a series of washes with different HEPES buffers and centrifugation. Four fractions 
were obtained: cytoplasmic, nuclear, membrane and cytoskeletal. These were validated 
by immunoblotting against different protein markers to their expected compartmental 
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fractions.  Again, protein concentrations for each sample were measured using a BCA 
kit.   
 
 
Western Blot:  
For western blot, the protein samples were diluted with the buffer used for lysis and 
loading buffer (Laemmli buffer and β-mercaptoethanol) in a 1:1 ratio.  The samples were 
heated at 95°C on a heating block for 10 minutes, cooled on ice, and then centrifuged.  
Equal amounts of protein were then loaded on 4-20% Tris-glycine gels and 
electrophoresed at 125V for 1.5 hours. Proteins were transferred to activated PVDF 
membranes via iBlot semi-dry system.  The membranes were quickly washed with PBS, 
and then blocked with LI-COR TBS Blocking buffer for 2 hours before incubating 
overnight with primary antibodies (NR1: Millipore Cat# 05-432, GluR2: Santa Cruz Cat# 
sc-7611, pCREB: Cell Signaling Cat# 9198).  The membranes were washed three times 
in TBS solution with 0.01% Tween, then incubated with LI-COR IR-detectable 
secondary antibodies for one hour at room temperature.  Finally, the membranes were 
washed again with TBS Tween, followed by PBS, and imaged using the Odyssey 
Infrared Imaging system (LI-COR Biosciences).  Bands were compared with protein 
loading standards. 
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3. Results 
 
Contextual fear conditioning: 
We were able to confirm that there is a significant memory deficit in 7-month old 5XFAD 
mice compared to their age-matched WT counterparts, using single-trial CFC (see Fig. 
26 inset from ref 7) to measure baseline freezing responses (Fig. 26, p<0.05).  We also 
confirmed no significant differences in males vs. females (not shown). 
 
 
 
Figure 26. 5XFAD mice exhibit CFC deficit at 7 months of age. Basic 
single-trial CFC testing differences between B6SJL mice and 5XFAD mice at 
7-months of age. Data are means ± SEM, n=6/group *p<0.05 two-tailed t-test. 
Inset shows the single-trial protocol (adapted from ref 7). 
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These baseline results allowed us to proceed to rescue experiments wherein 500nM 
Aβ1-15 or saline were microinjected bilateraly (0.40µL/side) into the dorsal hippocampi of 
5XFAD mice just prior to CFC training. First, as expected, the 5XFAD mice injected with 
saline had significantly lower freezing levels compared to B6.SJL mice injected with 
saline (Fig. 27, p<0.05). The 5XFAD mice injected with Aβ1-15 showed freezing levels 
comparable to WT mice with no memory deficits.  This indicates that Aβ1-15 was able to 
rescue (reverse) the 5XFAD mouse memory deficit in comparison to 5XFAD mice 
injected with saline, which showed very little freezing behavior (Fig. 27, p<0.005). No 
significant differences were observed in males vs. females (not shown). 
 
Figure 27. Bilateral delivery of 500nM Aβ1-15 into the dorsal hippocampus rescues 
memory deficit in 5XFAD mice to normal WT levels. Mice were trained for CFC single-
trial paradigm using a mild foot shock 24h before testing. 500nM Aβ1-15 or sterile saline 
were bilaterally injected into the dorsal hippocampi 20mins before training.  Freezing was 
measured via TSE videotracking software. Conditioned freezing was assessed by two 
trained observers.  (**p<0.005 comparing 5XFAD mice injected with Aβ1-15 to saline). Data 
are means ± SEM, n=5-6/group. One way ANOVA with Bonferroni post hoc tests..7,8 
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We repeated the single trial CFC test 24 hours after the initial test, and followed 
with a remote memory test 12 days later to examine the duration of memory 
improvement.  Mice were placed in the context of shock and observed for freezing for 
three minutes.  Again, the 5XFAD mice injected with Aβ1-15 12 days earlier retained 
normal levels of freezing that were significantly higher than saline injected 5XFAD mice 
(Fig. 28, p<0.05). For all tests, there was no difference in locomotion or sensory 
processing between B6.SJL and 5XFAD mice (not shown), confirming that differences 
observed in CFC were due to altered memory processing. 
Figure 28.  Bilateral delivery of 500nM Aβ1-15 into the dorsal hippocampus 
rescues memory deficit in both CFC (24h later) and remote memory CFC (12d 
later) in 5XFAD mice. Conditions as described in figure 26. CFC (24h) and Remote 
memory CFC (12d) in 5XFAD mice injected with Aβ1-15 or saline controls. Data are 
means ±_SEM, n=6-7/group *** p<0.001, *p<0.05 two-tailed t-test7,8  
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 To further examine the memory rescue, we tested for any benefits of the core 
fragment (Aβ10-15) in the 5XFAD mice.  As the core fragment has been confirmed by our 
lab to be the active sequence of the Aβ1-15 peptide2, this would further confirm its 
neuroprotective and memory rescue potential.  As expected, Aβ10-15 resulted in similar 
memory rescue as Aβ1-15 in both memory tests, 24 hours later and the 12-day remote 
memory test, with significantly higher freezing measured in groups injected with Aβ10-15 
than the saline control groups (Fig. 29, p<0.01). There was an unusual increase in 
freezing for the 5XFAD group injected with saline after 12 days, but the freezing 
response remained significantly reduced compared to the 5XFAD injected with the core 
fragment. 
Figure 29.  The N-terminal core fragment Aβ10-15 rescues memory deficit in 
both CFC (24h later) and remote memory CFC (12d later) in 5XFAD mice. 
Training and injection conditions as described in figure 26 with the core fragment 
instead Aβ1-15. CFC and Remote memory CFC in 5XFAD mice injected with Aβ10-15 
or saline controls. Data are means ± SEM, n=3-4/group **p<0.01 two-tailed t-test 
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Novel Object Recognition: 
The novel object recognition test was performed to examine whether Aβ1-15 is able to 
rescue recognition memory in the 5XFAD mouse.  As part of the 3-day test, we 
assessed thigmotaxia on the first day (habituation).  While differences were not 
significant between groups in these preliminary experiments, likely due to the smaller 
sample size (esp. B6.SJL mice), the B6.SJL mice were much less likely to explore the 
center of the open field than were the 5XFAD mice (Fig. 30), indicating an increase in 
exploratory behavior by the 5XFAD mice and/or a decrease in anxiety. 
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Figure 30.  5XFAD mice exhibit hyperexploratory behavior with more time 
spent in the center of an open field. Thigmotaxia in open field for B6SJL vs. 
5XFAD mice was measured via TSE videotracking software Data are means ± 
SEM, n=3/group for B6SJL, n=7/group for 5XFAD. 	
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Total distance traveled was also collected on each day to rule out any motor 
deficits that could affect the NOR (or CFC) test results.  On the first day of NOR there 
were significant differences in the total distance traveled between the B6.SJL group 
injected with Aβ1-15 versus both the 5XFAD group injected with saline (Fig. 31, p<0.05) 
and the 5XFAD group injected with Aβ1-15  (Fig. 31, p<0.01).  On the second day of NOR 
there were no significant differences in total distance traveled between groups but there 
was a significant increase in total distance traveled, likely due to the objects being 
explored.   
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Figure 31. Total distance traveled on days 1, 2 and 3 of NOR showed significant differences 
between WT and 5XFAD mice. 500nM Aβ1-15 or sterile saline were bilaterally injected into the 
dorsal hippocampi 20mins before day 2 training.  Total distance travelled in an open field was 
measured via TSE videotracking software *p<0.05 showing a significant difference between 
B6SJL mice injected with Aβ1-15   compared to 5XFAD mice injected with saline; **p<0.005 
5XFAD injected with Aβ1-15 on day 1; *p<0.05 significant differences between B6SJL mice treated 
with saline compared to 5XFAD mice treated with saline on Day 3. Data are means ± SEM, 
n=3/group for B6SJL, n=7/group for 5XFAD. 
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Day 3 of NOR showed similar distances traveled as day 2 with a significant 
difference of total distance traveled between B6.SJL and 5XFAD mice treated with the 
N-terminal fragment (Fig. 31).   
  Novel object recognition test results showed all groups had a preference for the 
novel object except for the B6.SJL saline group, with no significant differences between 
the groups with the preference for the novel object (Fig. 31). 
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Figure 32. No differences exhibited in novel object preference in B6.SJL and 
5XFAD mice injected with Aβ 1-15 or saline. 500nM Aβ1-15 or sterile saline were 
bilaterally injected into the dorsal hippocampi 20mins before day 2 training.  Time 
spent exploring each object was measured via TSE videotracking software and data 
are presented as percent exploration with exploration over 50% indicating a 
preference for that object.  Data are means of percent of time spent with each object 
Data are means ± SEM, n=3/group for B6SJL, n=7/group for 5XFAD. 
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Elevated Plus Maze: 
The elevated plus maze is a well-established test of anxiety.  We investigated if the 
injection of 0.40µL of 500nM Aβ1-15 would have an effect on the 5XFAD mice which 
tend to be hyper-exploratory compared to their wild-type counterparts.83 We first looked 
at total distance traveled to rule out any motor deficits and found no significant 
differences between groups (Fig. 33).  
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Figure 33. No significant differences in distance travelled between groups 
in elevated plus maze. Distance traveled in WT and 5XFAD mice injected with 
500nM Aβ1-15 or saline into the dorsal hippocampus 24h before EPM. Total 
distance traveled was collected using TSE videotracking software. Data are 
means ±SEM, n=3/group for B6SJL, n=7/group for 5XFAD. 
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After Aβ1-15 injections, 5XFAD mice spent significantly more time exploring open arms, 
signifying a decrease in anxiety (Fig. 34, p<0.05).  B6.SJL mice showed a non-
significant but similar trend.  
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Figure 34. 5XFAD mice injected with Aβ1-15 exhibit lower anxiety compared to 
saline injected 5XFAD mice. Percent of time spent in open arms in WT and 5XFAD 
mice injected with 500nM Aβ1-15 or saline into the dorsal hippocampus 24h before 
EPM test was measured by TSE videotracking software and percent of time spent in 
open arms is plotted. (*p<0.05) Data are means ±SEM, n=2-3/group for B6SJL, 
n=7/group for 5XFAD. 
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Intracellular Signaling – Immunoblot analysis: 
Lastly, we preliminarily explored possible molecular changes occurring with Aβ1-15 
injection by extracting compartment proteins from hippocampi from B6.SJL and 5XFAD 
mice injected with Aβ1-15, or saline. We probed for changes in pJNK and pERK. We also 
explored changes in receptor regulation by looking at NMDAR subunit NR1 and AMPAR 
subunit, GluR2 in the membrane fraction, both of which are essential for LTP. Lastly, we 
investigated pCREB signaling in the nuclear fraction.  CREB activation is essential for 
memory processing and is perturbed in AD patients.84–86 
We observed a clear downregulation of NR1 subunits in the membrane fraction 
of 5XFAD animals compared to B6.SJL mice.  The B6.SJL mice injected with Aβ1-15 
exhibited a slight decrease in NR1, while the 5XFAD mice injected with Aβ1-15 displayed 
a slight increase in NR1 (Fig. 35).   
 
 
 
Figure 35. Membrane NR1 is lower in 5XFAD mice compared to WT counterparts. 
Hippocampi collected 24h after microinjections of 500nM Aβ1-15 or saline in B6.SJL and 
5XFAD mice.  Compartment protein extraction was achieved using a compartmental protein 
extraction kit. Mean signal normalized to Cadherin loading control compared to saline 
injected B6SJL mice. Lane 1 upper and lower panel: 100kDa. n=1/group 
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Similarly, GluR2 levels are lower in the saline-injected 5XFAD mice compared to 
the saline-injected wild-type B6.SJL mice.  Injection of Aβ1-15 induced an upregulation of 
AMPA receptor subunit GluR2 in both the B6.SJL mice as well as the 5XFAD mice (Fig. 
36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. GluR2 levels are lower in 5XFAD mice compared to WTs with  Aβ
1-15 injection increasing mGluR2 levels in bot 5XFAD and WT mice. mGluR2 
mean signal normalized to cadherin loading control compared to saline injected 
B6SJL mice. Hippocampi collected 24h after microinjections of 500nM Aβ1-15 or 
saline in B6.SJL and 5XFAD mice.  Compartment protein extraction was achieved 
using a compartmental protein extraction kit. Lane 1 upper and lower panel: 
100kDa. n=3/group. 
135kDa 
 99kDa 
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Total CREB levels were found to be substantially lower in 5XFAD mouse 
hippocampi in comparison to the B6.SJL mouse hippocampi, consistent with previous 
findings.84 Injection of the N-terminal Aβ1-15 fragment led to upregulation of 
phosphorylated CREB in both wild-type and 5XFAD mice, with a more pronounced (2-
fold) upregulation in 5XFAD mice (Fig. 37). There was only a modest, insignificant 
increase in total CREB in the 5XFAD hippocampi with injection of Aβ1-15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. pCREB levels are lower in 5XFAD mice compared to WTs with  Aβ1-
15 injection increasing pCREB in both 5XFAD and WT mice. pCREB mean signal 
normalized to total CREB previously normalized to actin loading control (from 
cytoplasmic fraction of the same samples). Hippocampi collected 24h after 
microinjections of 500nM Aβ1-15 or saline in B6.SJL and 5XFAD mice.  Compartment 
protein extraction was achieved using a compartmental protein extraction kit. Lane 1 
upper and lower panel: 37kDa. n=1/group. 
43kDa 
43kDa 
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Discussion	
Current studies examining cognition in AD mouse models have used everything from 
metal chelating agents to HDAC6 inhibitors, β-secretase inhibitors, and even anti-
epileptic drugs to rescue memory.77,87,88  Many of these agents have deleterious effects 
due to the presence of multiple substrates limiting the specificity of action or have very 
limited beneficial effects. Even current treatments like NMDA antagonists and 
cholinesterase inhibitors are proving to only be useful in the early stages of AD, and 
only for limited symptomatic treatment among a limited population of patients.75,89 
In this study we show that Aβ1-15 is able to rescue (restore) memory in CFC up to 
twelve days post training in 5XFAD mice, and up to 7.5 months of age.  This is very 
promising considering this model has accelerated Aβ production with intraneuronal Aβ 
deposits observed at 2 months of age. Thus, this treatment shows potential for positive 
effects late in the pathology of AD.90 The mechanism by which this occurs is still 
unknown.  We were also able to demonstrate a decrease in anxiety via EPM in 5XFAD 
mice injected with Aβ1-15 compared to saline injected mice with a similar trend in B6.SJL 
mice suggesting an anxiolytic effect of Aβ1-15. Furthermore, all animals showed a 
preference for the novel object in NOR, suggesting that recognition memory was not 
affected in 5XFAD mice, though the exploratory behavior was.   
We investigated changes in intracellular signaling induced by bilateral Aβ15 
injections into the hippocampi of the mice as first, preliminary step toward uncovering 
the means by which the N-terminal Aβ peptide rescues 5XFAD memory deficits. We 
focused on mGluR and NR1 levels, subunits of AMPA receptors and NMDA receptors, 
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respectively, and pCREB.  As major players in long-term potentiation and memory, 
changes in these proteins would most reflect changes in LTP and behavior. 
We observed a slight upregulation of NR1 in Aβ15 injected 5XFAD mice. In 
contrast, mice injected with Aβ15 had a very pronounced upregulation of both mGluR2 
and activated CREB compared to their saline-injected counterparts.  This gives us a 
clue as to what could possibly be occurring with Aβ15 injection or perfusion. We know 
that activated CREB (pCREB) is able to bind BDNF promoters and increase AMPA 
receptor activity (ref).  AMPA receptor insertion is imperative for LTP and this 
upregulation can partially explain the memory enhancement observed in the Aβ15 
injected 5XFAD mice, which otherwise show substantial memory deficits. Altered 
regulation and expression of CREB has been identified as a central signaling deficit in 
Alzheimer’s disease85,86, as CREB activity is crucial to memory91,92 That pCREB levels 
were corrected with Aβ1-15 injection in the 5XFAD hippocampus while also significantly 
upregulated in the wild-type hippocampus strongly supports the direct effect of the N-
terminal Aβ1-15 fragment peptide on the primary signaling pathways for memory 
processing. 
Previous studies have also indicated that chronic Aβ42 application to hippocampal 
slice cultures activates JNK/MAPK and inhibits ERK/MAPK pathways, suggesting a way 
that Aβ42 impairs memory, due to the fact that ERK1/2 are important signaling molecules 
in learning and memory.35 While our data were inconclusive for JNK and ERK (data not 
shown), these would be important to further explore to determine if Aβ1-15 is able to 
prevent the effects of the toxic Aβ42 on JNK and ERK activation. With such a robust 
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phenotypic enhancement, further studies investigating how the N-terminal fragment 
enhances memory and prevents actions of the full-length toxic peptide are essential to 
further elucidating its mechanism of action.  
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CHAPTER 5 
Conclusions 
 
 
 
 
 
 
 
	 91	
Concluding Remarks 
 
Previous work in the Nichols lab established a toxicity timeline for Aβ1-42 in the model 
neuronal system we utilize, and confirmed its activation of MAPK-linked toxicity 
pathways.57 In conjunction with that, we have also previously shown that the Aβ1-15 
fragment, which is endogenously present in the CSF of healthy adults, indicating its 
presence in brain, is highly potent and more effective than Aβ1-42 in its agonist-like 
action via nAChRs.2 Due to its short, hydrophilic, nontoxic nature, we hypothesized that 
Aβ1-15 could have a neuroprotective role against the toxic full length Aβ1-42. 
This study confirmed that Aβ1-15 is neuroprotective in the differentiated NG108-15 
neuronal cell model by assessing non-specific ROS production as well as nuclear 
fragmentation that has been previously reported following treatment of cells with toxic, 
full-length Aβ.  Aβ1-15 treatment with various dosages and timing showed the N-terminal 
fragment protected against the well-established Aβ42 toxicity (Figs. 11 & 12). We also 
examined cell survival over one week treatment to examine whether the neuroprotection 
in the NG108-15 cells was limited to the ROS study timeline of three days. We observed 
that the neuroprotection by Aβ1-15 persisted throughout the seven-day time course, 
showing a lasting neuroprotective effect of Aβ1-15 (Fig. 13).  
To further investigate this neuroprotection, we then examined this effect in the 
more physiologically relevant primary hippocampal neuron culture.  We investigated 
toxicity and neuroprotection at different time points (5 and 10 days), examining the 
ability of Aβ1-15 to protect against Aβ42 toxicity.  As hypothesized, it was necessary to 
use higher concentrations (1µM) of Aβ42 to kill the primary cultures, and Aβ1-15, at the 
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same concentration, or even at 100nM, was able to protect these cultures from Aβ42 
toxicity (Fig. 15 & 16).  Similar to cell-survival in the NG108-15 cell line, we examined 
Aβ1-15 neuroprotection in the primary neurons over 10 days and observed similar ability 
of the N-terminal fragment to significantly protect against Aβ42 toxicity (Fig.18). The 
results from these model neuronal systems indicate several possible actions by the N-
terminal fragment in neuroprotection, including competitive block of Aβ42, anti-apoptotic 
signaling, and anti-oxidative pathway activation.  The extent these possibilities underlie 
the neuroprotective action of Aβ1-15 remains to be determined. 
Furthermore, Aβ42 has been shown to perturb synaptic function and prevent long-
term potentiation, so we studied the effects of Aβ1-15 on LTP and examined whether it 
could prevent the LTP block by Aβ42.7,64 These electrophysiological studies showed that 
Aβ1-15 was able to enhance LTP in wild-type acute hippocampal slices at very low 
concentrations as well as prevent the block of LTP by Aβ42 (Fig. 20).  In fact, perfusion 
of slices with Aβ1-15 for 20 minutes before the perfusion of Aβ42 completely ameliorates 
any LTP deficits caused by Aβ42 and allows for LTP at normal control levels.  The most 
promising of the LTP experiments examined LTP rescue in APPswe mice.  APPswe 
mice have a familial Swedish mutation that causes accelerated Aβ production and have 
been reported to have LTP deficits.  The perfusion of brain slices with Aβ1-15 was able to 
rescue LTP to control levels (Fig. 21). Toxic Aβ42 perturbs LTP by reducing NMDARs, 
and prompting NMDAR-mediated calcium influx inducing excitotoxicity, and activating 
stress pathways that result in synaptic dysfunction.  Our electrophysiology results 
suggest that Aβ1-15 might prevent LTP inhibition by Aβ42 due to competitive block, or 
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upregulation of AMPARs.  Further studies are required to determine the specific 
mechanisms involved in Aβ1-15 LTP rescue.  
To complement the electrophysiology experiments, we explored different 
behavior paradigms using the 5XFAD mouse model: a mouse model for AD with 3 
different familial APP mutations and two presenilin mutations, which exhibits 
accelerated Aβ production, leading to memory deficits within 6 months of age.  We 
showed that Aβ1-15 was able to rescue fear memory in contextual fear conditioning as 
well as reduce anxiety in the elevated plus maze further cementing Aβ1-15’s ability to 
rescue memory (Fig. 27, 28 & 34). In parallel with behavior, we explored changes in 
membrane NR1 and GluR2 levels as well as activated CREB and observed a very large 
upregulation of GluR2 and phosphorylated CREB giving us insight into the actions of 
Aβ1-15 (Fig. 35-37). Of particular note, CREB has been linked to memory in the brain, 
and the Aβ1-15-mediated reversal of its downregulation by Aβ42 may be part of the N-
terminal fragments primary action to rescue the memory deficits in the 5XFAD mice.  
Taken together, the current study highlights the neuroprotective effects of Aβ1-15 
against oxidative stress and neurodegeneration caused by Aβ42, its ability to prevent 
synaptic dysfunction, and its ability to rescue memory deficits in an AD mouse model. 
These data support the hypothesis that Aβ1-15 is neuroprotective against Aβ42 toxicity 
mediated by any and all of its target receptors. The capability to show these effects by 
an endogenous peptide in physiologically relevant models is confirmation that this 
peptide could lead to a new avenue for AD therapies. 	
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Future Directions 
 
This study has established that the N-terminal fragment, Aβ1-15 has a neuromodulatory 
function, is neuroprotective against Aβ42 toxicity in neuroblastoma and hippocampal 
primary neuron cultures, is able to enhance LTP, prevent Aβ42 LTP block, rescue LTP in 
APPswe mice, and is able rescue contextual fear memory in 5XFAD mice.  While this 
peptide shows high potential to be a candidate for AD therapy, there are many avenues 
that should be explored further.  These include, but are not limited to: 
1. Determine the crystal structure for both Aβ1-15 and Aβ10-15 in complex with 
nAChRs to determine their precise binding into the ligand-activation pocket. This 
will provide important information for future derivation of the N-terminal Aβ 
fragment peptides, particular for development of peptidomimetics. 
2. Binding by Aβ1-15 should be explored in depth.  This could be achieved via 
membrane binding studies to determine steady-state kinetic parameters (IC50) 
and competitive binding between Aβ1-15 and Aβ42. This will also provide essential 
information for development of peptide derivatives. 
3. Examine how Aβ1-15 is taken up by the neurons and the amount of time it takes 
for it to be degraded by tagging Aβ1-15 and looking at the amounts in serum and 
brain tissue in a time-dependent manner after injection. 
4. Investigate changes in synapse morphology and/or synapse density with Aβ1-15 
vs. saline (acute vs. chronic treatment) in 5XFAD mice. This can be achieved 
using Golgi staining or electron microscopy. 
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5. Larger scale electrophysiology and behavior experiments with more elaborate 
controls should also be performed.  We can explore whether N-terminal Aβ 
peptides can promote sub-threshold potentiation, which can push short-term 
potentiation to long-term potentiation.  In addition, the effect of Aβ1-15 on LTD 
should also be explored, as the LTD mechanism is as important as LTP for 
learning and memory.  
6. The N-terminal core fragment Aβ10-15 should be more intensively studied.  As the 
core of the N-terminal fragment is responsible for its activity, it has high potential 
to be developed as a peptidomimetic, optimized to cross the blood-brain barrier. 
(The original peptides would be predicted to poorly cross the blood-barrier.) If an 
identified peptidomimetic is confirmed to have similar effects as that seen with 
the Aβ1-15 and Aβ10-15 in both LTP and behavior, pharmacokinetic studies could 
then be performed, examining oral or intranasal bioavailability for potential 
therapeutic application. 
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